Microsoft word - bjgcv.doc

CURRICULUM VITAE
Barry J. Goldstein, M.D., Ph.D., F.A.C.E.
Academic Office: Room 349 Alumni Hall, 1020 Locust Street, Philadelphia, PA 19107
Clinical Office:
Suite 600, Walnut Towers, 211 S. 9th Street, Philadelphia, PA 19107
Phone: (215)
Fax: (215)
Medical License

Current Position:
Director, Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical College, Philadelphia, PA Professor of Medicine and Biochemistry and Molecular Pharmacology, Thomas Jefferson University, Philadelphia, PA Education:
B.S. (with Distinction) Cornell University, Ithaca, NY M.D. (with Honor) University of Rochester School of Medicine, Rochester, NY Ph.D. (Biochemistry) University of Rochester School of Medicine
Postdoctoral Training:

Internship and Residencies:
Intern in Medicine, Strong Memorial Hospital, Rochester, NY Associate Resident in Medicine, Strong Memorial Hospital
Fellowships:
1986-88
Research Fellow in Medicine, Harvard Medical School, Boston, MA Research Fellow, Section on Cellular and Molecular Physiology, Elliott P. Joslin Research Laboratory, Joslin Diabetes Center, Boston, MA Research/Clinical Fellow, Divisions of Endocrinology, Diabetes and Metabolism, Department of Medicine, Brigham and Women’s Hospital, Boston, MA Licensure and Certification:
1983
Diplomate, National Board of Medical Examiners Certified, American Board of Internal Medicine of Endocrinology, Diabetes and Metabolism
Academic Appointments:
Clinical Instructor in Medicine, University of Rochester Instructor in Medicine, Harvard Medical School Assistant Professor of Medicine, Harvard Medical School Director, Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical College, Thomas Jefferson University (TJU), Philadelphia, PA Associate Professor of Biochemistry and Molecular Pharmacology, TJU Professor of Biochemistry and Molecular Pharmacology, TJU Professor of Medicine (with Academic Tenure), TJU Hospital Appointments:
Associate Attending Physician, Highland Hospital, Rochester, NY Associate Physician, Brigham and Women’s Hospital, Boston, MA Active Attending Staff, Thomas Jefferson University Hospital, Philadelphia, PA Active Medical Staff, Wills Eye Hospital, Philadelphia, PA Active Medical Staff, Methodist Hospital, Philadelphia, PA
Other Professional Positions and Major Visiting Appointments:
1988-92
Investigator, Section on Cellular and Molecular Physiology, Elliott P. Joslin Research Laboratory, Joslin Diabetes Center, Boston, MA Affiliate Medical Staff, Joslin Diabetes Center, Boston, MA
Awards and Honors:
1975
Phi Kappa Phi Undergraduate Honor Society B.S. with Distinction, Cornell University, Ithaca, New York NIH Medical Scientist (M.D./Ph.D.) Program Fellowship Student Fellowship, Rochester Regional Diabetes Association Rochester Regional Diabetes Association, Research Award M.D. with Honor, University of Rochester School of Medicine Doran Stephens Award, University of Rochester School of Medicine Pfizer Postdoctoral Fellowship Award (Diabetes) Diamond Award and Key Contribution Award, Harvard Community Health Plan The Medical Foundation of Boston, Research Award American Diabetes Association, Research and Development Award Session Chair, Insulin Action, 15th IDF Congress, Kobe, Japan Outstanding Investigator Award, Dept. of Medicine, Jefferson Medical College John R. Williams Lectureship, Highland Hospital, University of Rochester Elected to the American Society for Clinical Investigation Edward Rose Lectureship, Philadelphia Endocrine Society Elected to Fellowship, American College of Endocrinology Frank A. Bove Memorial Lectureship, Methodist Hospital, Thomas Jefferson University Elected to the Association of American Physicians (AAP)
Editorial and Review Activities:
Associate

Editorial
American Journal of Physiology (Endocrinology and Metabolism) Endocrine, Metabolic & Immune Disorders - Drug Targets CMEonDiabetes, web-based CME curriculum (www.CMEonDiabetes.com) International Journal of Clinical Practice Clinical Medicine: Endocrinology and Diabetes (Open access)
Curriculum Development
1996
Conference syllabus consultant, Outcomes & Disease Management of Diabetes INCE Teleconferences on Diabetes Mellitus conducted nationwide COMED Teleconferences on Diabetes Management conducted nationwide Section Editor, Endocrinology and Diabetes, eMedicine on-line textbook Advisory Board for Special Report on Insulin Resistance, American Pharmaceutical Advisory Board for Endocrine Society Monograph: “Handbook on Obesity in America”
Manuscript Reviews:
1989-
Endocrinology, Journal of Clinical Endocrinology and Metabolism, Diabetologia Diabetes, Journal of Clinical Investigation, Journal of Biological Chemistry, Journal of Receptor Research, Molecular Endocrinology, Metabolism Biochemistry, American Journal of Physiology, Diabetes Care European Journal of Biochemistry, American Journal of Medicine Life Sciences, Steroids, Molecular and Cellular Biology Cell Metabolism, Nature Clinical Practice Endocrinology & Metabolism
Abstract Reviews:
1995
American Diabetes Association Annual Meeting Scientific Sessions International Congress of Endocrinology Scientific Sessions
Certification Examinations:
American Board of Internal Medicine
1992-1995 Physician Secretary, Self-Evaluation (Recertification) Program Subcommittee
for Endocrinology, Diabetes and Metabolism 1996-2002 Physician Secretary, Subspecialty Board on Endocrinology, Diabetes and Metabolism
Grant Proposals:
1990-
Veteran’s Administration Medical Research Service Member, Special Review Committee DK-93-10, “Human Genes for NIDDM” Special Reviewer, Metabolism Study Section Regular Member, Metabolism Study Section Ad Hoc Reviewer, Metabolism Study Section Ad Hoc Reviewer, Endocrinology Study Section NIH Special Emphasis Review Panel for NIH Roadmap Initiative RFA Ad Hoc Reviewer, Cellular Aspects of Diabetes and Obesity (CADO) Study Section Program project study section for Diabetes and Metabolism Reviewer, Special Emphasis Panels, CADO Study Section Corporate Consulting and Advisory Board Activities:
1998-00
HMR Oaktree Health Plan Pharmacy and Therapeutics Committee Scientific Advisory Board, Animas Corporation Diabetes Advisory Board, GlaxoSmithKline EMEA Steering Committee on Metabolic Consequences of HIV/HAART Algorithm Review Faculty, Institute for Healthcare Quality, Inc. Scientific Advisory Board, Wyeth-Ayerst Research Diabetes Advisory Board, AstraZeneca Pharmaceuticals Scientific Advisory Board, DelRx Corporation (insulin delivery devices) Consultant: Tularik; Medinox; Lilly ICOS Scientific Advisory Board, BristolMyers Squibb; KOWA corporation Consultant , ONO Corporation; Barr Pharmaceuticals Member, Clinical Trial Outcomes Adjudication Committee, GlaxoSmithKline Scientific Advisory Board, Ortho Clinical Diagnostics Scientific Advisory Board, Omentec Pharmaceuticals Data Safety Monitoring Board, Wyeth Research Clinical Trials Endpoint Adjudication Committee, GlaxoSmithKline APPROACH study Consultant, MetaBasis Therapeutics, Dainippon Sumitomo Pharma Membership and Activities in Professional Societies:
1984-
Greater Philadelphia and Southern New Jersey Region Speaker, Endocrinology Review Section, IM Board Recert Course American Association for the Advancement of Science American Federation for Clinical Research American Society for Biochemistry and Molecular Biology 1994-95 Secretary/Treasurer 1995-96 Vice Association of Program Directors for Endocrinology and Metabolism American Association of Clinical Endocrinologists 1997-1999 Member, Endocrine Training Liaison Committee
1992-2003 American Board of Internal Medicine
1993-
American Society for Clinical Investigation (ASCI) Interurban Clinical Club (Osler Society) Association of American Physicians (AAP) Multicenter NIH Clinical Trials Activities
NIH: Action to Control Cardiovascular Risk in Diabetes (ACCORD)
2004-
Member, External Hypoglycemia Monitoring Committee NIH: Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS) 1996- Member, Outcomes Classification / CVD and Glucose Adjudication Committee
Basic Research Grants:
1976-82
NIH Medical Scientist (M.D./Ph.D.) Training Program Fellowship Student Fellowship Grant-in-Aid, Rochester Diabetes Association Pfizer Postdoctoral Fellowship Grant (Diabetes) The Medical Foundation of Boston, Postdoctoral Research Grant Award NIH DK36836, Diabetes/Endocrinology Research Center, PI, Pilot and Feasibility Study: “Cloning of the Rat Liver Insulin Receptor cDNA” NIH R01 DK31036, Co-Investigator, “Insulin Receptor Structure and Turnover” American Diabetes Association, Research and Development Award, “Molecular Cloning of Hepatic Protein-Tyrosine Phosphatases” NIH R01 DK43396, PI, “Protein-Tyrosine Phosphatases in Insulin Action” NIH R01 DK45592, PI, “Insulin Action in Liver from NIDDM and Obese Humans” Wyeth-Ayerst Research, PI, “Large-Scale Expression and Purification of PTPases” National Institutes of Health, Co-Inv., Type 1 Diabetes Prevention Trial 1994-2002 NIH U01 DK48468, Co-PI, Diabetes Prevention Program (DPP) 2001- NIH R01 DK43396, PI, “Protein-Tyrosine Phosphatases in Insulin Action” (Renewal) Juvenile Diabetes Found., PI, “Insulin Action in PTPase Knock-out Mice” Bayer Pharmaceuticals, PI, “Development of Lines of PTPase Knock-out Mice” Hoffman-LaRoche, PI, “PTPase Expression in Insulin-Resistant States.” Animas Corporation, PI, “FTIR Spectroscopic Investigation of Blood from Patients for the Accurate Measurement of Blood Glucose.” Tolz Fund Grant (Weizmann Institute/Jefferson), Co-Inv., “Regulation of Insulin Receptor Trafficking by its Downstream Effectors: Role of Annexin II and IRS-1.” NIH R01 DK53388, PI, “Tyrosine Phosphatases in Human Obesity and Diabetes” American Diabetes Association, Mentor-Based Post-Doctoral Fellowship Grant NIH R01 DK43396, PI, “Protein-Tyrosine Phosphatases in Insulin Action” (Renewal) NIH U01 DK48468, PI, Diabetes Prevention Program Outcomes Study (DPPOS) Amer Diab Assoc, PI, “Adiponectin: Effects on Endothelial Function and Insulin Signaling” 2004-05 Thomas Jefferson Pilot Grant Program, “Insulin Signaling and Diabetic Nephropathy in Transgenic Models Lacking Expression of the NAD(P)H Oxidase Homolog Nox4.” NIH RO1 DK063018 PI, "Adiponectin: Vascular Responses and Signaling Mechanisms" NIH RO1 DK071360 PI, “Adiponectin Improves Vascular Function In High Glucose” GlaxoSmithKline, PI, Investigator-Initiated Basic research project, "Are the Effects of Rosiglitazone on Endothelial Function in Insulin Resistance Mediated by Adiponectin? NIH R01 DK43396, PI, “Protein-Tyrosine Phosphatases in Insulin Action” (Renewal) PA Dept. Public Health (C.U.R.E.) Program, Co-Inv, Ma (PI), “Adiponectin: Cardioprotective effects and signaling mechanisms” American Diabetes Association, Co-Inv, Ma (PI), “Reactive Nitrogen Species and Dept. of the Army 03163015, Co-Inv, Joseph (PI), “Artificial Pancreas for Control of Blood Glucose in Hospitalized Patients with Diabetes and Stress Hyperglycemia” PA Dept. Public Health , Co Inv, Falkner (PI) Center of Excellence on Research in Obesity NIH U01 DK076133, Co-Inv, Sharma (PI), “Adiponectin and Nox4 in Diabetic Kidney
Clinical Research Grants:
1993-4
Lilly, PI, LY275585 vs. Humulin R: Premeal therapy in new type 2 patients. Lilly, Co-Inv., LY275585 vs. Humulin R: Premeal therapy in type 2 diabetes patients. Miles, Co-Inv., Miglitol (BAY m1099) in African-American NIDDM patients. 1993-94 Pratt Pharmaceuticals, Co-investigator, Glipizide GITS efficacy and safety trial. 1994-95 Lilly, PI, Long term monitoring of safety in patients treated with LY275585. Alteon/Marion Merrell Dow, PI, Aminoguanidine in diabetic nephropathy. Novo-Nordisk, PI, Comparison of BID 70/30 prefilled with QD Novolin-N Amylin, PI, Tri-pro-amylin in subjects with type 1 diabetes. Sanofi, PI, Intermittent cyclical tiludronate in post-menopausal osteoporosis. Parke-Davis, PI, Placebo-controlled study of troglitazone in type 2 diabetes. SmithKline Beecham, PI, BRL49653C (rosiglitazone) in type 2 diabetes. Alteon, Co-PI, Aminoguanidine in diabetic patients with ESRD on dialysis. Genentech, Inc., PI, Recombinant hIGF-1 with insulin in type 2 diabetes mellitus. Novo-Nordisk, Inc., PI, Repaglinide in type 2 diabetes: maintenance study. SmithKline Beecham, PI, BRL 49653C therapy in patients with NIDDM. Parke-Davis, Co-Inv., CI-991 on treatment targets in insulin-taking NIDDM diabetes SmithKline Beecham, PI, Safety and efficacy of BRL 49653C as monotherapy. SmithKline Beecham, PI, BRL49653C added to glyburide in type 2 diabetes. Hoechst Marion Roussel, PI, HOE 901 vs. NPH human insulin in type 1 diabetes. Futrex, Inc., PI, Calibration and performance of a non-invasive blood glucose meter Bristol-Myers Squibb, PI, Metformin XR monotherapy in type 2 diabetes Lilly, Co-Inv., 3.0 mL disposable pen study. Novo Nordisk, Inc., Co-Inv., Insulin and C-peptide responses to repaglinide in type 2 SmithKline Beecham, PI, BRL49653C BID with glyburide in type 2 diabetes. Pfizer, Co-Inv., A study of inhaled human insulin monotherapy in type 2 diabetes. Bristol-Myers Squibb, PI, Fixed combination metformin/glyburide in T2DM. SmithKline Beecham, PI, Rosiglitazone/glyburide open label extension study SmithKline Beecham, PI, Rosiglitazone with glyburide and metformin in T2DM SmithKline Beecham, PI, Rosiglitazone with glipizide in elderly type 2 diabetes. Exocell, Co-Inv., Anti-glycation agent, EXO-226 on renal dysfunction in diabetic patients. Glaxo Wellcome, PI, GI262570 vs. glyburide or in combination in T2DM. Glaxo Wellcome, PI, GI262570 in combination with insulin in type 2 diabetes. Pfizer, Co-Inv., Long term safety of inhaled human insulin in type 1 or type 2 diabetes. Bristol Myers Squibb, PI, Rosiglitazone added to Metformin/Glyburide in T2DM. Bristol Myers Squibb, PI, Fixed combination metformin/glipizide in type 2 diabetes. Genzyme, Co-Inv., Diagnostic utility of Thyrogen®)-stimulated thyroglobulin for the surveillance of patients with treated papillary or follicular thyroid carcinoma. AstraZeneca, PI, Phase II study of AR-H039242 in patients with type 2 diabetes. Takeda, PI, Hepatic safety of pioglitazone vs. glyburide with metformin and insulin in T2DM Bristol Myers Squibb, PI, Omapatrilat CV treatment assessment versus enalapril (OCTAVE). BioStratum, PI, Pyridoxamine in nephropathy in Type 1 Diabetes BioStratum, PI, Pyridoxamine in nephropathy in Type 2 Diabetes Amylin, PI, Effect on glucose control of AC2993 given two times a day in subjects with type 2 diabetes mellitus treated with metformin or sulfonylurea or combination of met/SU. Aventis 4034, Co-Inv., Effect of Amaryl® in patients treated with Avandia® monotherapy. DepoMed, PI, Metformin ER tablets vs. metformin IR tablets in T2DM GlaxoSmithKline, Co-Inv., Effect of rosiglitazone on lipids in diabetic subjects taking GlaxoSmithKline, PI, Carvedilol vs. metoprolol on glycemic control in hypertensive patients Hoffman LaRoche, Co-Inv., Efficacy, safety, tolerability and pharmacokinetics of RO 205 in Wyeth Ayerst, PI, Safety and efficacy of 4 doses of PTP-112 in patients with type 2 diabetes. Amylin Corp., PI, A phase 3, randomized, multicenter study of AC2993 given two times a day in subjects with Type 2 DM treated with Metformin alone. Amylin Corp., PI, A phase 3, randomized, multicenter study of AC2993 given two times a day in subjects with Type 2 DM treated with a sulfonylurea alone. Aventis, PI, Insulin glargine injection vs. pioglitazone (Actos) as add-on. Chugai Pharma, PI, A 12-week, placebo-controlled study to evaluate the safety and efficacy of GM-611 in patients with diabetic gastroparesis. Nutrition 21, PI, Chromium effects on insulin resistance and glycemic control in Type 2 DM 2000-03 Exocell, Co-inv., A double blind, randomized, multicenter, study of the effect of the anti- glycation agent, EXO-226, on renal dysfunction in two strata of albuminuric diabetic patients. Lilly, PI, Plasma adiponectin and glycemic control in Type 1 and Type 2 DM Merck, PI, Multicenter, double blind, randomized, active-controlled, parallel study in patients with Type 2 diabetes to evaluate the cardiac and metabolic effects of MK-0767. Merck, PI, Multicenter, randomized study of the addition of MK-0767 to patients with Type 2 DM on combined metformin and sulfonylurea therapy Merck, Co-inv., Double-blind, randomized, active-controlled MK-0767 and metformin comparator study in Type 2 diabetic patients inadequately controlled on diet and exercise GlaxoSmithKline, Co-inv., Multicenter, randomized, placebo controlled evaluation of rosiglitazone in combination with glimepiride in subjects with Type 2 DM Lilly, Co-inv., Global hypopituitary control and complications study (HypoCCS) Aventis, PI, ORIGIN: Insulin glargine/ω-3 fatty acids in reducing cardiovascular morbidity and mortality in people with IFG, IGT or early T2DM NovoNordisk, PI, NovoLog® mix 70/30 BID with metformin and pioglitazone compared to metformin and pioglitazone alone in insulin-naïve subjects with T2DM KOWA, PI, Multicenter, randomized Phase IIA study of the addition of K-111 to patients with Type 2 DM suboptimally controlled on metformin therapy AstraZeneca, PI, Multicenter placebo-controlled study to evaluate tesaglitazar therapy in patients with type 2 diabetes mellitus poorly controlled on insulin (GALLANT 9) 2004-05 AstraZeneca, PI, Randomised, Multicenter, open label study to analyze renal mechanisms of creatinine excretion in patients on tesaglitazar (ARMOR) Sankyo, Co-Inv., Randomized, double-blind, placebo-controlled 12-week efficacy and safety study of CS-917 in patients with Type 2 Diabetes 2005-06 AstraZeneca, PI, Multicenter study of tesaglitazar therapy in patients with T2DM 2005-06 Thomas Jefferson University Hospital & Medtronic Minimed, Co-inv., Nocturnal glucose fluctuations with once daily glargine insulin vs. insulin pump therapy Merck, PI, Multicenter, randomized study of the co-administration of MK-0431 and metformin in patients with T2DM who have inadequate glycemic control AstraZeneca, PI, Open label multicenter, long-term extension study of tesaglitazar when added to insulin therapy in patients with T2DM Sanofi-Aventis, PI, AVE0010 (exendin-4 analog) with Metformin in T2DM ONO, PI, Phase IIa study of ONO-5129 (PPAR α/γ agonist) in treatment-naïve T2DM NovoNordisk, PI, Liraglutide safety and efficacy vs. Glimepiride in T2DM Mannkind, Co-Inv., Subcutaneous basal insulin and prandial inhalation of Technosphere® insulin vs. subcutaneous premixed insulin GlaxoSmithKline, Co-Inv., GW677954 (pan-PPAR agonist) monotherapy or add-on therapy Sanofi-Aventis, PI, Rimonabant 20 mg daily for reducing risk of CV events in abdominally- obese patients with clustering risk factors (CRESCENDO) Bristol-Myers Squibb, PI, Saxagliptin (BMS-477118; DPP-IV inhibitor) in combination with TZD in patient with T2DM and inadequate glycemic control Sanofi-Aventis, PI, Dose-ranging study of AVE7688 in hypertension (ACE-NEP) Roche, Co-Inv., Phase 2 study of a glucokinase activator (RO4389620) in T2DM Boehringer, Co-Inv., Efficacy and safety of BI 1356 BS in T2DM Lifescan / Diabetech, PI, Facilitating Glycemic Control via Telemetric Acquisition and Computer-Assisted Compilation of Blood Glucose Data Merck, Co-Inv, Safety and efficacy of sitagliptin in elderly patients with T2DM NovoNordisk, PI, inhaled mealtime AERx insulin versus SC insulin aspart in combination Sanofi-Aventis, PI, AVE0010 in Metformin-Treated Subjects with Type 2 Diabetes Mellitus Merck, PI, Phase 3 trial of sitagliptin added to metformin and TZD in uncontrolled T2DM Takeda, PI, Efficacy and safety of SYR-322 with or without pioglitazone in T2DM subjects Merck, PI, Multicenter, randomized, double-blinded factorial study of the co-administration of sitagliptin and metformin in patients with T2DM Merck, PI, Phase 3 multicenter, randomized, double-blinded study of adding sitagliptin to T2DM patients with inadequate control on insulin (alone or in combination with metformin). Takeda, PI, Long-term, open-label extension study SYR-322 in T2DM NovoNordisk, Co-Inv., Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma Amylin Pharmaceuticals, Co-Inv., Basal Insulin Intensified With Either SYMLIN® or Rapid Lilly, Co-Inv., Durability of BD Insulin Lispro Low Mixture Compared to QD Insulin Glargine when added to Existing Oral Therapy in Patients with T2DM (DURABLE) Sanofi Aventis, PI. Glycemic Control with Rimonabant in Comparison with Glimepiride in Overweight/Obese T2DM Not Adequately Controlled with Metformin (Allegro) Daiichi Sankyo, PI, Rivoglitazone as Monotherapy Treatment of T2DM Major Research Interests:
1. Mechanisms and regulation of insulin receptor signal transduction.
2. Protein-tyrosine phosphatases and the regulation of hormone action.
3. Pathophysiology of insulin-resistant disease states including obesity and Type 2 diabetes mellitus.
4. Mechanisms of the complications of diabetes, including vascular signaling by adiponectin

Major Administrative Responsibilities:
1985-86
Director, Employee Health Service, Highland Hospital, Rochester, NY Director, Enrichment Core Programs, Joslin Diabetes Center, Boston, MA Director of Research, Joslin Center for Diabetes at Wills and Jefferson, Philadelphia, PA Director, Division of Endocrinology, Diabetes and Metabolic Diseases, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 1992-2004 Program Director, Fellowship in Endocrinology, Diabetes and Metabolism, Thomas Jefferson University Hospital, Philadelphia, PA
Principal Clinical and Hospital Service Responsibilities:
1985-86
Medical Staff Physician, Highland Hospital, Rochester, NY Attending Physician, Diabetes and Metabolism, Brigham and Women’s Hospital, Boston, MA Attending Physician, Endocrinology and Metabolism, Thomas Jefferson University Hospital Residency Candidate Interviewer, Thomas Jefferson University Hospital
Committee Activities:
Thomas Jefferson University Hospital 1992- Bedside Glucose Quality Improvement Team Out-Patient Diabetes Education Program Advisory Committee Diabetes Therapy Working Group, Pharmacy and Therapeutics Committee Advisory Council for the Diabetes Self-Management Education Program Jefferson Medical College 1993-94 Coordinator, Endocrinology/Metabolism/Diabetes Clinical Research Interest Groups Faculty Participant, Training Program in Clinical Pharmacology (Endocrinology) Advisory Committee, Medical Scientist (MD, PhD) Training Program Appointments and Promotions Committee, Department of Medicine 1997- Member 2006- Research Committee, Department of Medicine Clinical Competency Committee, Department of Medicine Residency Program Advisory Committee, Clinical Pharmacology Training Program in Human Investigation Executive Council, Clinical Science Representative Thomas Jefferson University 1993- Molecular Pharmacology and Structural Biology, Ph.D. Candidate Thesis Committees (S. Parkinson, S. Deshmane, O. Goodman, D. Emlet) Pharmacology M.S. Thesis Committees (N. Sedkova, A. Zilbering, J. Zizzamia, L. Fuchsel) Physiology Ph.D. Thesis Committees (G. Booth, T. Stalker) Biochemistry and Molecular Pharmacology Ph.D. Thesis Committees (R. Drakas) Faculty Incentives for Research Productivity Committee Standing Committee on Conflicts of Interest and Commitment Biomedical Chemistry M.S. Thesis Committee (A. Ochman) Molecular Pharmacology M.D./Ph.D. Thesis Committee Chair (B. DeGeorge) Biotechnology M.S. Thesis Committee (V. Patel)
Teaching Experience:
1975-76
Teaching Assistant, Microbial Genetics, Cornell University, Ithaca, NY Ambulatory Medical Clinic, Highland Hospital, Rochester, NY Fellowship Program, Research Division, Joslin Diabetes Center Diabetes Consult Service, Brigham and Women’s Hospital, Boston, MA Director, Longwood Area Diabetes/Metabolism Seminar Series, Harvard Medical School Harvard-Joslin Postgraduate Course on Type II Diabetes, Boston, MA Patient Lecture Series, Joslin Diabetes Center, Boston, MA Senior Thesis Reader, Harvard-M.I.T. Division of Health Sciences Program Director, 1995 Jefferson Endocrinology and Diabetes Symposium Program Director, National Diabetes Education Initiative Saturday Seminar, Philadelphia, PA
Jefferson Medical College Teaching Responsibilities
1992-
Teaching Attending, Residency Program, Jefferson Medical College Fellowship Program in Endocrinology, Diabetes and Metabolism, TJUH Medical Residents Patient Management Conferences, Jefferson Medical College Biochemistry 100, Clinical Correlation Lectures on Diabetes Mellitus Introduction to Clinical Medicine, ICM 202: Physical Exam: Endocrinology Section Program in Nutrition Seminars, Management of the Diabetic Patient Pharmacology 401, Endocrine Disorders: Thyroid Gland and Adrenal Glands Pharmacology 522, Endocrine Systems: Insulin Action Co-Director, Pharmacology 702, Frontiers in Modern Endocrinology Primary Introduction to the Patient, ICM 203, Section Attending Molecular Pharmacology 680, Protein-tyrosine Phosphatases Doctor in Health and Illness: office-based experience for freshman students Clinico-Pathological Integrative Conference, Diabetic Retinopathy, Sophomore Class Scientific Foundations of Clinical Medicine, Review of Diabetes Mellitus for 4th year ORIGINAL REPORTS
1. Goldstein BJ, Zahler SA. Uptake of branched chain α-keto acids in Bacillus subtilis. J Bacteriology
1976; 127:667-670.
2. Zahler SA, Benjamin LG, Glatz BS, Winter PF, Goldstein BJ. Genetic mapping of alsA, alsR, thyA,
kauA, and citD Markers in Bacillus subtilis. In: Schlessinger D, ed. Microbiology 1976. American
Society for Microbiology: Washington, D.C., 1976; PP. 35-43.
3. Goldstein BJ, Livingston JN. Effects in adipocytes of diamide on GSH levels, glucose uptake and
cell integrity. Biochim Biophys Acta 1978; 513:99-105
4. Goldstein BJ, Livingston JN. Insulin degradation by adipose tissue: Studies at several levels of
cellular organization. Biochem J 1980; 186:351-360
5. Goldstein BJ. Insulin degradation by adipocytes: Significance of neutral cytosol protease activity.
Ph.D. Thesis, University of Rochester School of Medicine and Dentistry, 1980.
6. Goldstein BJ, Livingston JN. An evaluation of the importance of lysosomal and neutral cytosol
proteases in insulin degradation by adipocytes. Endocrinology 1981; 108:953-961
7. Goldstein BJ, Hanna K, Bullous skin ulceration in a man with myelofibrosis. Hospital Practice 1986;
21:102-104.
8. Goldstein BJ, Mushlin AI. Use of a single thyroxine test to evaluate ambulatory medical patients for
suspected hypothyroidism. J Gen Intern Med 1987;2:20-24.
9. Goldstein BJ, Müller-Wieland D, Kahn CR. Variation in insulin receptor messenger ribonucleic acid
expression in human and rodent tissues. Molecular Endocrinology 1987; 1:759-766.
10. Ludwig S, Müller-Wieland D, Goldstein BJ, Kahn CR. The insulin receptor gene and its expression
in insulin-resistant mice. Endocrinology 1988; 123:594-600.
11. Goldstein BJ, Kahn CR. Initial processing of the insulin receptor precursor in vivo and in vitro. J
Biol Chem 1988; 263:12809-12812.
12. Kwok CG, Goldstein BJ, Müller-Wieland D, Lee TS, Kahn CR, King GL. Identification of persistent
defects in insulin receptor structure and function in capillary endothelial cells from diabetic BB rats. J
Clin Invest 1989; 83:127-136.
13. Goldstein BJ, Kahn CR. Analysis of mRNA heterogeneity by ribonuclease H mapping: Application
to the insulin receptor. Biochem Biophys Res Comm 1989; 159:664-669.
14. Goldstein BJ, Kahn CR. Insulin receptor messenger RNA sequence alterations detected by
ribonuclease cleavage in patients with syndromes of insulin resistance. J Clin Endocrinol Metab 1989;
69:15-24.
15. Goldstein BJ, Dudley AL. The rat insulin receptor: Primary structure and conservation of tissue-
specific alternative messenger RNA splicing. Molecular Endocrinology 1990; 4:235-244.
16. Davison G, Suchman AL, Goldstein BJ. Reducing unnecessary coronary care unit admission: a
comparison of three decision aids. J Gen Intern Med 1990; 5:474-479.
17. Goldstein BJ, Dudley AL. Molecular heterogeneity of insulin receptors in rat tissues. Adv Exp Med
Biol 1991; 293:187-195.
18. Goldstein BJ, Meyerovitch J, Zhang W-R, Backer JM, Csermely P, Hashimoto N, Kahn CR. Hepatic
protein-tyrosine phosphatases and their regulation in diabetes. Advances in Protein Phosphatases 1991;
6:1-17.
19. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden P, Cahill DA, Goldstein BJ, White
MF. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein.
Nature 1991; 352:73-77.
20. Zhang W-R, Goldstein BJ. Identification of skeletal muscle protein-tyrosine phosphatases by
amplification of conserved cDNA sequences. Biochem Biophys Res Comm 1991; 178:1291-1297.
21. Goldstein BJ, Zhang W-R, Hashimoto N, Kahn CR. Approaches to the molecular cloning of protein-
tyrosine phosphatases in insulin-sensitive tissues. Mol Cell Biochem 1992; 109:107-113.
22. Hashimoto N, Zhang W-R, Goldstein BJ. Insulin receptor and epidermal growth factor receptor
dephosphorylation by three major rat liver protein-tyrosine phosphatases expressed in a recombinant
bacterial system. Biochem J 1992; 284:569-576.
23. Chatterjee S, Goldstein BJ, Csermely P, Shoelson SE. Design and synthesis of potent substrates and
inhibitors of protein-tyrosine phosphatases. In: Rivier JE, Smith JA, eds. Peptides: Chemistry and
Biology. Escom Science Publishers, Leiden, Netherlands. 1992; pp. 553-555.
24. Goldstein BJ, Dudley AL. Heterogeneity of messenger RNA encoding the rat insulin receptor is
limited to the domain of exon 11. Analysis by RNA heteroduplex mapping, amplification of cDNA and
in vitro translation. Diabetes 1992; 41:1293-1300.
25. Hashimoto N, Feener EP, Zhang W-R, Goldstein BJ. Insulin receptor protein-tyrosine phosphatases:
Leukocyte common antigen-related phosphatase rapidly deactivates the insulin receptor kinase by
preferential dephosphorylation of the receptor regulatory domain. J Biol Chem 1992; 267:13811-13814.
26. Hashimoto N, Goldstein BJ. Differential regulation of mRNAs encoding three protein tyrosine
phosphatases by insulin and activation of protein kinase C. Biochem Biophys Res Comm 1992;
188:1305-1311.
27. Kriauciunas KM, Goldstein BJ, Lipes MA, Kahn CR. Modulation of expression of insulin and IGF-I
receptor by Epstein-Barr virus and its gene products LMP and EBNA-2 in lymphocyte cell lines. J
Cellular Physiology 1993; 154:486-495.
28. Baskin DG, Schwartz MW, Sipols AJ, D’Alessio DA, Goldstein BJ, White MF. Insulin receptor
substrate-1 (IRS-1) expression in rat brain. Endocrinology 1994; 134:1952-1955.
29. Zhang W-R, Hashimoto N, Ahmad F, Ding W, Goldstein BJ. Molecular cloning and expression of a
unique receptor-like protein-tyrosine phosphatase in the leukocyte common antigen-related (LAR)
phosphatase family. Biochem. J. 1994; 302:39-47.
30. Rotin D, Goldstein BJ, Fladd CA. Expression of the protein-tyrosine phosphatase LAR-PTP2 is
developmentally regulated in lung epithelia. Am. J. of Physiol 1994; 267:L263-270.
31. Ding W, Zhang WR, Sullivan K, Hashimoto N, Goldstein BJ. Identification of protein-tyrosine
phosphatases prevalent in adipocytes by molecular cloning. Biochem. Biophys. Res. Comm. 1994;
202:902-907.
32. Ahmad F, Goldstein BJ. Increased abundance of specific skeletal muscle protein-tyrosine
phosphatases in a genetic model of obesity and insulin resistant diabetes mellitus. Metabolism 1995;
44:1175-1184.
33. Kulas DT, Zhang WR, Goldstein BJ, Furlanetto RW, Mooney RA. Insulin receptor signaling is
augmented by antisense inhibition of the protein-tyrosine phosphatase LAR. J. Biol. Chem. 1995;
270:2435-2438.
34. Ahmad F, Goldstein BJ. Purification, identification and subcellular distribution of three predominant
protein-tyrosine phosphatase enzymes in skeletal muscle tissue. Biochim. Biophys. Acta, 1995; 1248:57-
69.
35. Ahmad F, Goldstein BJ. Alterations in specific protein-tyrosine phosphatases accompany the insulin
resistance of streptozotocin-diabetes. Am. J. Physiol. 1995; 268:E932-E940.
36. Ahmad F, Considine R, Goldstein BJ. Increased abundance of the receptor-type protein-tyrosine
phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue
of obese human subjects. J. Clin. Invest. 1995; 95:2806-2812.
37. Ahmad F, Li PM, Meyerovitch J, Goldstein BJ. Osmotic loading of neutralizing antibodies
demonstrates a role for PTPase1B in negative regulation of the insulin action pathway. J. Biol. Chem.
1995; 270:20503-20508.
38. Kulas DT, Goldstein BJ, Mooney RA. The transmembrane protein tyrosine phosphatase LAR
modulates signaling by multiple receptor tyrosine kinases. J. Biol. Chem. 1996; 271:748-754.
39. Li PM, Goldstein BJ. Cell density-dependent changes in the insulin action pathway: Evidence for
involvement of protein-tyrosine phosphatases. J. Cellular Biochem. 1996; 61:31-38.
40. Kim H, Yeger H, Han R, Goldstein BJ, Rotin D. Expression of the tyrosine phosphatase LAR-PTP2
in rat lung is developmentally regulated and confined to undifferentiated epithelia lining the airways and
air sac. Am. J. Physiol. 1996; 270:L566-L576.
41. Zhang W-R, Li P-M, Oswald MA, Goldstein BJ. Modulation of insulin signal transduction by
eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR. Mol. Endocrinol. 1996;
10:575-584.
42. Li PM, Zhang WR, Goldstein BJ. Suppression of insulin receptor activation by overexpression of the
protein-tyrosine phosphatase LAR in hepatoma cells. Cellular Signaling 1996; 8: 467-473.
43. Li PM, Goldstein BJ. Differential regulation of insulin-stimulated tyrosine phosphorylation of IRS-1
and Shc by wortmannin in intact cells. Biochem. Biophys. Res. Comm., 1996; 223:80-84.
44. Saito S, Hashimoto N, Tokita K, Toyoda M, Suzuki Y, Goldstein BJ, Suzuki H, Makino H, Saito Y.
Changes in expression of phosphotyrosine phosphatases in rat hepatocellular carcinoma induced by 3’-
methyl-4-dimethylamino-azobenzene. Biochem. Biophys. Res. Comm. 1996; 227:406-412.
45. Ahmad F, Goldstein BJ. Effect of tumor necrosis factor-α on the phosphorylation of tyrosine kinase
receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases. J. Cellular
Biochem. 1997; 64:117-127.
46. Ahmad F, Goldstein BJ. Functional association between the insulin receptor and the transmembrane
protein-tyrosine phosphatase LAR in intact cells. J. Biol. Chem. 1997; 272:448-457.
47. Ahmad F, Azevedo J, Cortright R, Dohm GL, Goldstein BJ. Alterations in skeletal muscle protein-
tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes, J. Clin.
Invest. 1997; 100:449-458.
48. Ahmad F, Considine RV, Bauer TL, Ohannesian JP, Marco CC, Goldstein BJ. Improved sensitivity
to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine
phosphatases in adipose tissue. Metabolism 1997; 46:1140-1145.
49. Kolaczynski JW, Goldstein BJ, Considine RV. Dexamethasone, OB gene and leptin in humans:
Effect of exogenous hyperinsulinemia. J. Clin Endocrinol. Metab. 1997; 82:3895-3897.
50. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW and the Troglitazone Study
Group troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a
randomized, controlled study. J Clin Endocrinol Metab 1998; 83:3169-3176
51. Ren JM, Li PM, Zhang WR, Sweet LJ, Cline G, Shulman GI, Livingston JN, Goldstein BJ.
Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose
homeostasis. Diabetes 1998;47:493-497.
52. Kole HK, Kole S, Mallory BP, Li PM, Goldstein BJ, Bernier M. Inhibition of the transmembrane
PTPase LAR by 3S-peptide-I enhances insulin receptor phosphorylation in intact cells. Revs Clin Basic
Pharmacol 1998; 9:2-4.
53. Ohannesian JP, Marco CC, Najm PS, Goldstein BJ, Caro JF, Kolaczynski JW. Small weight gain is
not associated with development of insulin resistance in healthy, physically active individuals. Horm.
Metab. Res. 1999; 31:323-325.
54. Diabetes Prevention Program Study Group. The Diabetes Prevention Program: Design and Methods
for a Clinical Trial in the Prevention of Type 2 Diabetes Mellitus. Diabetes Care 1999;22:623-634.
55. Toyoda M, Hashimoto N, Tokita K, Goldstein BJ, Yokosuka O, Kanatsuka A, Suzuki Y , Saito Y.
Increased activity and expression of MAP kinase in HCC model rats induced by 3-methyl-4-
dimethylamino-azobenzene. J Hepatology 1999; 31:725-733.
56. Solow BT, Harada S, Goldstein BJ, Smith JA, White MF, Jarett L. Differential modulation of the
tyrosine phosphorylation state of the insulin receptor by IRS Proteins. Mol Endo 1999; 13: 1784 – 1798.
57. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: A 24-
week, fixed-dose efficacy and safety study. J Clin Pharm 2000; 40:49-57.
58. Goldstein BJ, Bittner-Kowalczyk A, White MF, Harbeck M. Tyrosine dephosphorylation and
deactivation of insulin receptor substrate-1 by protein tyrosine phosphatase 1B. Possible facilitation by
the formation of a ternary complex with the GRB2 adapter protein, J. Biol. Chem 2000; 275:4283-4289.
59. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky G, Kahn
CR. Metabolic effects of vanadyl sulfate in humans with non-insulin dependent diabetes mellitus: in
vivo and in vitro studies. Metabolism 2000; 49:400-410.
60. Diabetes Prevention Program Study Group. The Diabetes Prevention Program: Baseline
Characteristics of the Randomized Cohort. Diabetes Care 2000; 11:1619-1629.
61. Tang S, Le-Tien H, Goldstein BJ, Shin P, Lai R, Fantus IG. Decreased insulin receptor dephosphor-
ylation in hyperglycemia and hyperinsulinemia-induced insulin resistance in rat adipocytes is associated
with decreased LAR protein tyrosine phosphatase content and activity. Diabetes 2001; 50:83-90.
62. Zhu L, Zilbering A, Wu X, Mahadev K, Joseph JI, Jabbour S, Deeb W, Goldstein BJ. Use of an
Anaerobic Environment to Preserve the Endogenous Activity of Protein-Tyrosine Phosphatases Isolated
from Intact Cells. FASEB J 2001;15:1637-1639. FASEB J express article published online 10.1096/fj.00-
0795fje.
63. Mahadev K, Zilbering A, Zhu L, Goldstein BJ. Insulin-Stimulated Hydrogen Peroxide Reversibly
Inhibits Protein-Tyrosine Phosphatase 1B in vivo and Enhances the Early Insulin Action Cascade, J. Biol.
Chem 2001;276:21938-21942.
64. Goldstein BJ, Zhu L, Hager R, Zilbering A, Sun Y, Vincent JB. Enhancement of Post-Receptor
Insulin Signaling by Trivalent Chromium in Hepatoma Cells May Involve Differential Inhibition of
Specific Protein-Tyrosine Phosphatases. J Trace Elements Exp Med 2001;14:393-404.
65. Wu X, Hoffstedt J, Deeb W, Singh R, Sedkova N, Zilbering A, Zhu L, Park PK, Arner P, Goldstein
BJ. Depot-Specific Variation in Protein-Tyrosine Phosphatase Activities in Human Omental and
Subcutaneous Adipose Tissue: A Potential Contribution to Differential Insulin Sensitivity. J Clin
Endocrinol Metab 2001;86:5973-5980.
66. Mahadev K, Wu X, Zilbering A, Zhu L, Lawrence JTR, Goldstein BJ. Hydrogen Peroxide Generated
During Cellular Insulin Stimulation Is Integral to Activation of the Distal Insulin Signaling Cascade in
3T3-L1 Adipocytes, J. Biol. Chem 2001; 276:48662-48669.
67. Torjman MC, Jahn L, Joseph JI, Crothall K, Goldstein BJ. Accuracy of the Hemocue Portable
Glucose Analyzer in a Large Non-Homogeneous Population. Diabetes Technology & Therapeutics 2001;
3:591-600.
68. Diabetes Prevention Program Research Group. The Diabetes Prevention Program: Recruitment
Methods and Results. Controlled Clinical Trials 2002; 23:157-171.
69. Zhu L, Goldstein BJ. Use of an Anaerobic Chamber Environment for the Assay of Endogenous
Cellular Protein-Tyrosine Phosphatase Activities. Biol. Proc. Online 2002; 4:1-9.
70. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with
Lifestyle Intervention or Metformin. N Engl J Med 2002; 346:393-403.
71. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ.
Differential Regulation of Adiponectin Secretion from Cultured Human Omental and Subcutaneous
Adipocytes: Effects of Insulin and Rosiglitazone. J Clin Endocrinol Metab 2002; 87:5662-5667.
72. Goldstein BJ, Cobitz AR, Hand LM, Chen H. Are the Metabolic Effects of Rosiglitazone Influenced
by Baseline Glycemic Control?, Curr Med Res Opin, 2003; 19:192–199.
73. The Diabetes Prevention Program Research Group. Effects of Withdrawal From Metformin on the
Development of Diabetes in the Diabetes Prevention Program. Diabetes Care 2003;26:977-980.
74. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated
Protein Kinase in Glucose Uptake Stimulated by Adiponectin in Primary Rat Adipocytes, Diabetes 2003;
52:1355–1363.
75. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment
of simultaneous glipizide/metformin therapy as second-line pharmacologic treatment for patients with
type 2 diabetes that is inadequately controlled by a sulfonylurea. Clin Ther 2003; 25:890-903.
76. Wu X, Hardy VE, Joseph JI, Jabbour S, Mahadev K, Zhu L Goldstein BJ. Protein-Tyrosine
Phosphatase Activity in Human Adipocytes is Strongly Correlated with Insulin-Stimulated Glucose
Uptake and is a Target of Insulin-Induced Oxidative Inhibition. Metabolism 2003;52:705-712.
77. Mazurek T, Zhang LF, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S,
Keiper EA, Johnson AG, Martin J, Martella A, Goldstein BJ, Shi Y. Human Epicardial Adipose Tissue is
a Source of Inflammatory Mediators. Circulation 2003;108:2460-2466.
78. Mahadev K, Wu X, Motoshima H, Goldstein BJ. Integration of Multiple Downstream Signals
Determines the Net Effect of Insulin on MAP Kinase vs. PI 3’-Kinase Activation: Potential Role of
Insulin-Stimulated H2O2. Cell Signal. 2004;16:323-331.
79. Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, Lambeth JD, Goldstein BJ. The
NADPH Oxidase Homolog Nox4 Modulates Insulin-Stimulated Generation of H2O2 and Plays an Integral
Role in Insulin Signal Transduction. Mol Cell Biol, 2004;24:1844-1854.
80. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide
generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys
Res Comm, 2004;315:264-271.
81. Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on
cardiovascular (CVD) risk factors in the Diabetes Prevention Program. Diabetes Care 2005;28:888-94.
82. Wu XD, Zhu L, Zilbering A, Mahadev K, Motoshima H, Yao, JL, Goldstein BJ. Hyperglycemia
Potentiates H2O2 Production in Adipocytes and Enhances Insulin Signal Transduction: Potential Role for
Oxidative Inhibition of Thiol-Sensitive Protein-Tyrosine Phosphatases. Antioxidants & Redox Signaling,
2005;7:526-537.
83. Hu T, Ramachandra Rao S, Siva S, Valancius C, Zhu Y, Mahadev K, Toh I, Goldstein BJ, Woolkalis
M, Sharma K. Reactive oxygen species production via NADPH oxidase mediates TGF-β induced
cytoskeletal alterations in endothelial cells, Am J Physiol Renal Physiol 2005;289:F816-F825.
84. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz A, Wooddell MJ, Strow LJ. The
EMPIRE Study: Benefits of Rosiglitazone added to Submaximal doses of Metformin compared with
Dose Escalation of Metformin in Type 2 Diabetes, Curr Med Res Opin, 2005;21:2029-35.
85. Rosenstock J, Goldstein BJ, Vinik AI, O’Neill C, Porter L, Heise MA, Kravitz B, Dirani R, Freed MI,
and the RESULT Study Group. Effect of early addition of rosiglitazone to sulfonylurea therapy in older
type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULfonylurea Titration (RESULT)
study. Diabetes, Obesity and Metabolism, 2006;8:49-57.
86. Ouedraogo R, Motoshima H, Wu XD, Mahadev K, Hough K, Scalia R, Goldstein BJ. Adiponectin
Suppression of High Glucose-Induced Reactive Oxygen Species in Vascular Endothelial Cells: Evidence
for Involvement of a cAMP Signaling Pathway. Diabetes, 2006;55:1840-1846.
87. Goldstein BJ, Weissman P, Wooddell MJ, Waterhouse BR, Strow LJ. Reductions in Biomarkers of
Cardiovascular Risk in Type 2 Diabetes with Rosiglitazone Added to Metformin compared with Dose
Escalation of Metformin: An EMPIRE Trial Substudy. Curr Med Res Opin. 2006;22:1715–1723.
88. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Öhman KP. Effect of tesaglitazar, a dual PPARα/γ
agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
Curr Med Res Opin, 2006;22:2575–2590
89. Patel DN, Bailey, SR, Gresham JK, Schuchman DB, Shelhamer JH, Goldstein BJ, Foxwell BM,
Stemerman MB; Maranchie JK, Valente AJ, Mummidi S, Chandrasekar B. TLR4-NOX4-AP-1 signaling
mediates lipopolysaccharide-induced CXCR6 expression in human aortic smooth muscle cells. BBRC,
2006;347:1113-1120.
90. Nathan DM, Chew E, Christophi CA, Davis MD, Fowler S, Goldstein BJ, Hamman RF, Hubbard LD,
Knowler WC, Molitch ME for the Diabetes Prevention Program research Group. The prevalence of
retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program.
Diabetic Medicine 2007;24:137-144.
91. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher T, Lopez B, Koch W, Chan L, Goldstein BJ, Ma
XL. Adiponectin Cardioprotection following Myocardial Ischemia/Reperfusion Involves the Reduction of
Oxidative/Nitrative Stress. Circulation 2007;115:1408-1416.
92. Ouedraogo R, Gong Y, Berzins B, Wu XD, Mahadev K, Hough K, Chan L, Goldstein BJ, Scalia RG.
Adiponectin Deficiency Increases Leukocyte-Endothelium Interactions via Upregulation of Endothelial
Cell Adhesion Molecules In Vivo. J Clin Invest 2007;117:1718-26.
93. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, for the Sitagliptin 036
Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and
metformin on glycemic control in patients with type 2 diabetes. Diabetes Care, 2997, in press.
94. Chou HS, Palmer JP, Jones AR, Waterhouse B, Ferreira-Cornwell C, Krebs J, Goldstein BJ. Initial
treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated
type 2 diabetes. Diabetes, Obesity and Metabolism, in press.
95. Rosenzweig SA, Reibel DK, Greeson JM, Edman JS, Jasser SA, McMearty KD, Goldstein BJ.
Mindfulness-Based Stress Reduction is Associated with Improved Glycemic Control in Type 2 Diabetes
Mellitus: A Pilot Study. Altern Ther Health Med 2007; 13:36-38.
96. Li R, Wang W-Q, Zhang H, Yang X, Fan Q, Christopher TA, Lopez BL, Tao L, Goldstein BJ, Gao F,
Ma X-L. Adiponectin Improves Endothelial Function in Hyperlipidemic Rats by Reducing
Oxidative/Nitrative Stress and Differential Regulation of eNOS/iNOS Activity, Am J Physiol Endocrinol
Metab. published 25 September 2007; 10.1152/ajpendo.00462.2007
REVIEWS, CHAPTERS AND EDITORIALS
1. Goldstein BJ, Livingston JN. Progress in Endocrinology and Metabolism: Insulin degradation by
insulin target cells. Metabolism 1981; 30:825-835.
2. Goldstein BJ, Kahn CR. Insulin allergy and insulin resistance. In: Lichtenstein LM, Fauci AS, eds.
Current Therapy in Allergy, Immunology and Rheumatology. Lewiston, NY; B.C. Decker, Inc.
1988; pp, 327-330.
3. Kahn CR, Goldstein BJ, Shoelson SE. Mechanisms of insulin receptor activation and biosynthesis.
In Imura H, Shizume K, Yoshida S, eds. Progress in Endocrinology 1988. Amsterdam: Elsevier
Science Publishers B.V. 1988; pp. 371-376.
4. Kahn CR, Goldstein BJ. Perspective: Molecular defects in insulin action. Science 1989; 245:13
5. Kahn CR, Goldstein BJ, Reddy SSK. Hereditary and acquired syndromes of insulin resistance. In:
Pickup J, Williams G, eds. Textbook of Diabetes. Oxford, England: Blackwell Scientific Publications,
Ltd. 1991; pp. 276-285
6. Goldstein BJ. Protein-tyrosine phosphatases and the regulation of insulin action. J Cell Biochem
1992; 48:33-42.
7. Goldstein BJ, Kahn CR. Insulin receptors in normal and disease states. In: Alberti KGMM,
DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. Sussex,
England: John Wiley & Sons, Ltd. 1992; pp. 357-383.
8. Manning WJ, Goldberger AL, Drews RE, Goldstein BJ, Matheson JK, Rabinowe SL, Trentham DE,
Landsberg L. POEMS syndrome with myocardial infarction: observations concerning pathogenesis and
review of the literature. Sem Arthr Rheum 1992; 22:151-161.
9. Goldstein BJ. The menopause and diabetes: Exploring the connection. Menopause Management,
February, 1993, pp. 16-19.
10. Kahn CR, White MF, Shoelson SE, Backer J, Araki E, Cheatham B, Siddle K, Sun XJ, Wilden P,
Yamada K, Csermely P, Folli F, Goldstein BJ, Huertas P, Rothenberg PL, Saad MJ. The insulin receptor
and its substrate: Molecular determinant of early events in insulin action. In: Bardin CW, ed. Recent
Progress in Hormone Research, Vol. 48. Orlando: Academic Press. 1993; pp. 291-339.
11. Goldstein BJ Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation.
Receptor 1993; 3:1-15.
12. Goldstein BJ. Syndromes of extreme insulin resistance. In: Weir GC, Kahn CR, eds. Joslin’s
Diabetes Mellitus, 13th edition. Philadelphia: Lea & Febiger. 1994; pp. 282-299.
13. Goldstein BJ. Protein-tyrosine phosphatases and the regulation of insulin action. In: LeRoith D,
Olefsky JM, Taylor SI, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, PA:
JB Lippincott Co. 1996, pp. 174-186.
14. Garber AJ, Gavin JR III, Goldstein BJ. Insulin resistance, syndrome X, and type II diabetes. Patient
Care, June 15, 1996, pp.198-211.
15. Kolaczynski JW, Goldstein BJ. Glycation of hemoglobin and serum proteins as tools for monitoring.
In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes
Mellitus, 2nd edition. Sussex, England: John Wiley & Sons, Ltd. 1997.
16. Maratos-Flier E, Goldstein BJ, Kahn CR. The insulin receptor and postreceptor mechanisms. In:
Pickup J, Williams G, eds. Textbook of Diabetes, 2nd edition. Oxford, England: Blackwell Scientific
Publications, Ltd. 1997, pp 10.1-10.22.
17. Goldstein BJ. Three clinical case scenarios: “Compounded Confusion”, “Amenorrhea and
Galactorrhea”, and “Weak and Shaky Spells.” In: Cutler P, ed. Problem Solving in Clinical Medicine:
From Data to Diagnosis, 3rd ed. Baltimore, MD: Williams & Wilkins, 1998, pp 202-212.
18. Goldstein BJ, Ahmad F, Ding W, Li PM, Zhang WR. Regulation of the insulin signaling pathway by
cellular protein-tyrosine phosphatases. Mol Cell Endocrinol, 1998; 182:91-99.
19. Goldstein BJ, Li PM, Ding W, Ahmad F, Zhang WR. Regulation of insulin action by protein-
tyrosine phosphatases. Vitamins and Hormones, vol. 54, 1998, pp. 67-96.
20. Peters AL, Henry R, Edelman SV, Goldstein BJ. Keep metformin guidelines intact (Letter). Diabetes
Care 22: 532, 1999.
21. Goldstein BJ. Treatment of Type 2 Diabetes: Efficacy of Thiazolidinediones as Monotherapy.
Consultant 39:S21-S27, 1999.
22. Goldstein BJ. Current views on the mechanism of action of thiazolidinedione insulin sensitizers.
Diabetes Technology & Therapeutics 1:267-275, 1999.
23. Goldstein BJ, Wiegers SE. Treatment Strategies for Type 2 Diabetes: Anti-Hyperglycemics and
Cardiovascular Protection. Drug Benefit Trends 11(Suppl. B):11-34, 1999.
24. Goldstein BJ. Epidemiology and Pathogenesis of Type 2 Diabetes. In: Managed Care Interface,
1999, Medicom International, Inc., Bronxville, NY.
25. Kolaczynski JW, Goldstein BJ. The influence of obesity on the development of non-insulin-
dependent diabetes mellitus. In: Obesity: Pathology and Therapy, edited by D. H. Lockwood and T. G.
Heffner, Handbook of Experimental Pharmacology, Volume 149, New York:Springer-Verlag, 2000, p.
91-119.
26. Goldstein BJ. Regulation of insulin action by protein-tyrosine phosphatases. In: LeRoith D, Olefsky
JM, Taylor SI, eds. Diabetes Mellitus: A Fundamental and Clinical Text. 2nd Edition. Philadelphia,
PA: JB Lippincott Co. 2000, pp. 206-217.
27. Goldstein BJ. Drug Focus: Rosiglitazone. Int J Clin Prac, 2000; 54(5):333-337.
28. Jabbour SA, Goldstein BJ. Improving Disease Management with New Treatments for Type 2
Diabetes. Clinical Geriatrics, 2000; 8:44-56.
29. Goldstein BJ. Hyperinsulinemia in the Insulin Resistance Syndrome: Should it be the Target of
Treatment? Diab Rel Dis Newsletter, September 2000.
30. Jabbour SA, Goldstein BJ. Improving Disease Management with New Treatments for Type 2
Diabetes Mellitus. Clinical Geriatrics, Special issue on Geriatric Prescribing Options, 2001; 9:57-68.
31. Singh R, Wiegers S, Goldstein BJ. The Impact of Gender on Diabetes Mellitus and its Associated
Cardiovascular Risk Factors. Clinical Geriatrics, 2001;9:63-70.
32. Singh R, Wiegers S, Goldstein BJ. The Impact of Gender on Diabetes Mellitus and its Associated
Cardiovascular Risk Factors. Journal of Gender-Specific Medicine, 2001;4:28-36.
33. Goldstein BJ. Protein-Tyrosine Phosphatase 1B (PTP1B): A Novel Therapeutic Target for Type 2
Diabetes Mellitus, Obesity and Related States of Insulin Resistance. Current Drug Targets in Immune,
Endocrine and Metabolic Disorders, 2001;1:265-275.
34. Goldstein BJ. Insights from mouse models deficient in protein-tyrosine phosphatases that regulate
the insulin action pathway. In: Grunberger G, Zick Y, guest eds. Insulin Signaling: From Cultured
Cells to Animal Models. Oxford, England: Harwood Academic Press 2002, pp 35-50.
35. Goldstein BJ. Differentiating Members of the Thiazolidinedione Class: a Focus on Efficacy. Diabetes
Metab. Res. Rev. 2002;18:S16-S22.
36. Goldstein BJ. Protein-Tyrosine Phosphatases: Emerging Targets for Therapeutic Intervention in Type
2 Diabetes and Related States of Insulin Resistance. J Clin Endocrinol Metab 2002;87:2474–2480.
37. Goldstein BJ. Possible Vascular-Protective Effects of Antidiabetic Agents Such as the
Thiazolidinediones (Letter). Clin Ther 2002;24:1358-60.
38. Goldstein BJ. Pathogenesis of Type 2 Diabetes Mellitus: Insulin Resistance is a Core Defect.Am J
Cardiol 2002; 90(suppl):3G-10G.
39. Goldstein BJ. Diabetes Mellitus. In: Rubin E, ed. Pathology. Philadelphia: Lippincott-Williams &
Wilkins, 2003.
40. Goldstein BJ. Diabetes Mellitus. In: Gonnella JS, ed. Disease staging : clinical criteria, 5th ed.
2003.
41. Müller-Wieland D, Kotzka J, Goldstein BJ. Pathogenesis of type 2 diabetes. In: Goldstein BJ, Müller-
Wieland D, Eds. Textbook of Type 2 Diabetes. London: Martin Dunitz, 2003, pp. 13-28.
42. Jabbour SA, Goldstein BJ. Type 2 Diabetes: Geriatric Considerations. In: Goldstein BJ, Müller-
Wieland D, Eds. Textbook of Type 2 Diabetes. London: Martin Dunitz, 2003, pp. 409-422.
43. Joseph JI, Goldstein BJ. New Devices and Drugs on the Horizon. In: Goldstein BJ, Müller-Wieland
D, Eds. Textbook of Type 2 Diabetes. London: Martin Dunitz, 2003, pp. 447-460.
44. Goldstein BJ. Regulation of insulin action by protein-tyrosine phosphatases. In: LeRoith D, Olefsky
JM, Taylor SI, eds. Diabetes Mellitus: A Fundamental and Clinical Text. 3nd Edition. Philadelphia,
PA: JB Lippincott Co. 2003.
45. Goldstein BJ, Jabbour S, Ahmed I. Glycated hemoglobin and serum proteins as tools for monitoring.
In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes
Mellitus, 3rd edition. Sussex, England: John Wiley & Sons, Ltd. 2003.
46. Goldstein BJ. Insulin Resistance: From Benign to Type 2 Diabetes Mellitus. Rev Cardiovasc Med
2003;4(Suppl 6): S3-S10.
47. Goldstein BJ, Scalia R. Adiponectin: A Novel ‘Adipokine’ Linking Adipocytes and Vascular
Function, J Clin Endocrinol Metab, 2004;89:2563-2568.
48. Jabbour S, Anolik J, Goldstein BJ. Insulin-Sensitizing and Insulin-Sparing Drugs:
Thiazolidinediones and Metformin. In: Fonseca V, ed. Clinical Diabetes: Translating Research into
Practice. Philadelphia: Elsevier, 2005.
49. Goldstein BJ, Kalyankar M, Wu XD. Redox Paradox: Insulin Action is Facilitated by Insulin-
Stimulated Reactive Oxygen Species with Multiple Potential Signaling Targets. Diabetes 2005;54:311-
321.
50. Stumvoll M, Goldstein BJ, van Haeften, TW. Seminar: Type 2 Diabetes: – Principles of Pathogenesis
and Therapy. Lancet 2005;365:1333–46.
51. Goldstein BJ, Ahmed I. “Inflammatory” Signaling: Bridging Obesity-Linked Insulin Resistance with
Vascular Dysfunction. Diabetes und Stoffwechsel (German Diabetes Assoc. Journal) 2005;14:31-36.
52. Goldstein BJ, Ahmed I. Adiponectin: A New Hormone From Fat Cells (concise review). In: Kasper
DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJ (eds),
harrisonsonline.com. New York: McGraw-Hill, 2005.
53. Rosenberg D, Jabbour SA, Goldstein BJ. Insulin Resistance, Diabetes, and Cardiovascular Risk:
Approaches to Treatment. Diabetes, Obesity and Metabolism, 2005;7:642-653.
54. Goldstein BJ, Mahadev K, Wu XD, Zhu L, Motoshima H. Role of Insulin-Induced Reactive Oxygen
Species in the Insulin Signaling Pathway. Antioxidants and Redox Signaling, 2005;7:1021-31.
55. Goldstein BJ. Intensive insulin therapy regimens: is there a difference in patient satisfaction? Nature
Clin Pract Endocrinol Metab, 2005;1:80-81 (doi:10.1038/ncpendmet0054)
56. Goldstein BJ. Structure and Function of the Insulin Receptor. UpToDate (www.uptodate.com).
57. Goldstein BJ. Closing the gap between clinical research and clinical practice: can outcome studies
with thiazolidinediones improve our understanding of type 2 diabetes? Int J Clin Pract 2006;60:873-83
58. Ahmed I, Goldstein BJ. Cardiovascular Risk in the Spectrum of Type 2 Diabetes Mellitus. Mount
Sinai J Med, 2006;73:759-68.
59. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and Cell Proliferation: AMPK as a
Therapeutic Target for Atherosclerosis and Cancer, J Physiol, 2006;574:63-71.
60. Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR α/γ Agonists: Promises and Pitfalls
in Type 2 Diabetes. Am J Therapeutics, 2007;14:49-62.
61. Goldstein BJ, Scalia R. Adipokines and Vascular Disease in Diabetes. Curr Diab Rep, 2007;7:25–33.
62. Goldstein BJ. Clinical Translation of “A Diabetes Outcome Progression Trial”: ADOPT Appropriate
Combination Oral Therapies in Type 2 Diabetes. J Clin Endocrinol Metab, 2007;92:1226–1228.
63. Goldstein BJ, Mahadev K, Wu XD. Insulin-Stimulated Reactive Oxygen Species and Insulin Signal
Transduction. In: Packer L, Sies H, eds. Oxidative Stress and Inflammatory Mechanisms in Obesity,
Diabetes, and the Metabolic Syndrome. pp 178-187. Boca Raton, FL: Taylor and Francis, 2007.
64. Goldstein BJ, Scalia R, Ma XL, Mahadev K, Wu XD, Ouedraogo R. Letter to the Editor of
DIABETES re: Hattori et al. Globular Adiponectin Activates Nuclear Factor-{kappa}B and Activating
Protein-1 and Enhances Angiotensin II-Induced Proliferation in Cardiac Fibroblasts. Diabetes 56:804-
808, 2007.
MONOGRAPHS / BOOKS
1. Goldstein BJ. Phosphoprotein Phosphatases 1: Tyrosine Phosphatases. Volume 2, issue 13 In
Protein Profile, Sheterline P, series ed., London:Academic Press, 1995; pp.1425-1585.
2. Goldstein BJ, Kirchain WR, eds., Diabetes: Approaches in Disease Management, CMR Institute,
Roanoke, VA, 1997
3. Goldstein BJ. Tyrosine Phosphoprotein Phosphatases. 2nd edition, In Protein Profile, Sheterline P, series ed., London:Oxford University Press, 1998. 4. Goldstein BJ, Cotter VT, Morley JE, Setter SM. Type 2 Diabetes in the Long-Term Care Environment: A Practical Approach To Patient Care. Medical Education Systems, 1998. 5. Wender R, Caro J, Goldstein BJ, Plent S, eds. Caring for Diabetes: Evaluation and Management of Diabetes. CME monograph. Philadelphia: Aetna/USHealthcare, 1998. 6. Goldstein BJ, Gorstein F, Guest Editors. “Diabetes Mellitus”, Clinics in Laboratory Medicine, Philadelphia: Saunders, 2001. 7. Goldstein BJ, Guest Editor. A Symposium: Evolution of Type 2 Diabetes Management: Assessment and Clinical Application of Newer Findings. Suppl. to Am J Cardiol 2002;90(suppl):1G-50G. 8. Lenow JL, Capuzzi DM, Goldstein BJ, Morgan J. Recent Advances in the Treatment of Dyslipidemia in Patients with Type 2 Diabetes: Focus on Fibrate Therapy. CME monograph. Philadelphia: Jefferson Medical College, Thomas Jefferson University, 2003. 9. Goldstein BJ, Müller-Wieland D, Eds. Textbook of Type 2 Diabetes. London: Martin Dunitz, 2003. 10. Goldstein BJ, Hendrickson J, Rodriguez MR. Diabetes Management, module 2. Medication Therapy Management Services: Applying Compliance and Adherence Principles to Optimize Care of Patients with Diabetes. CE monograph for the American Pharmacists Association (AP'hA), 2006. GenBank SUBMISSIONS
Rat insulin receptor mRNA, complete cds. L11586 Rat leukocyte common antigen-related phosphatase (LAR) mRNA, complete cds.
L11587 Rat leukocyte common antigen-related phosphatase (LAR-PTP2) mRNA, complete cds.
L12329 Rat leukocyte common antigen-related phosphatase (LAR-PTP2B) alternatively-spliced
mRNA
U09307 Rat protein-tyrosine phosphatase (SH-PTP2) mRNA complete cds.
AY436318 Bovine adiponectin receptor (AdipoR1) sequence fragment
AY436319 Bovine adiponectin receptor (AdipoR2) sequence fragment
Application filed, Sharma KS and Goldstein BJ. For: “Adiponectin For The Treatment And Diagnosis Of Albuminuria” ABSTRACTS AND SCIENTIFIC PRESENTATIONS (since 1998)
1. Goldstein BJ, Harbeck MC, Zhang WR. Mechanisms of Tyrosine Dephosphorylation of the Insulin Receptor and IRS-1 by Candidate Protein-Tyrosine Phosphatases. VII International Symposium on Insulin Receptors & Insulin Action: Molecular and Clinical Aspects, May 1998, Jerusalem, Israel. 2. Harbeck MC, White MF, Goldstein BJ. PTP1B Efficiently Dephosphorylates IRS-1 and Deactivates its Adaptor Function in vitro: Evidence for Specificity Among a Series of Candidate Protein-Tyrosine Phosphatases. ADA Annual Meeting, June 1998, Chicago, IL. 3. Crothall KD, Jahn LG, Torjman MC, Butoi B, Goldstein BJ, Joseph J, Norris K. Development of an Implantable Spectroscopic Blood Glucose Sensor: In-Vitro Results with Whole Blood. ADA Annual Meeting, June 1999, San Diego, CA. 4. Crothall KD, Joseph J, Torjman MC, Jahn LG, Moritz MJ, Sullivan ME, Goldstein BJ, Butoi B. Development of an Implantable NIR Spectroscopic Blood Glucose Sensor: In-Vivo Results in Dogs. ADA Annual Meeting, June 1999, San Diego, CA. 5. Bittner-Kowalczyk A, Harbeck MC, Goldstein BJ. The Adaptor Protein Grb2 Enhances the Tyrosine Dephosphorylation of IRS-1 by Promoting a Stable Association Between IRS-1 and the Protein-Tyrosine Phosphatase PTP1B. ADA Annual Meeting, June 1999, San Diego, CA. 6. Solow BT, Harada S, Smith JA, Goldstein BJ, Jarett L. IRS-1 but not IRS-2 Differentially Modulates Insulin-Stimulated Tyrosine Phosphorylation of the Insulin Receptor. ADA Annual Meeting, June 1999, San Diego, CA. 7. Bittner-Kowalczyk A, Harbeck MC, Goldstein BJ. The Adaptor Protein Grb2 Enhances the Tyrosine Dephosphorylation of IRS-1 by Promoting a Stable Association Between IRS-1 and the Protein-Tyrosine Phosphatase PTP1B. Mid-Atlantic Diabetes Research Symposium, September 18, 1999, NIH, Bethesda, MD. 8. Goldstein BJ, Salzman A. Rosiglitazone is effective in poorly controlled type 2 diabetes patients. European Association for the Study of Diabetes Annual Scientific Meeting, September, 1999, Brussels, Belgium. 9. Goldstein BJ, Sedkova N, Hoffstedt J, Arner P. Differences in Protein-Tyrosine Phosphatase Activities May Contribute to the Depot-Specific Insulin Responsiveness of Adipose Tissue. American Diabetes Association Annual Meeting, June 2000, San Antonio, TX. 10. Goldstein BJ, Zhu L, Hager R, Zilbering A, Sun Y, Vincent JB. Enhancement of Post-Receptor Insulin Signaling by Trivalent Chromium in Hepatoma Cells May Involve Differential Inhibition of Specific Protein-Tyrosine Phosphatases. American Diabetes Association Annual Meeting, June 2000, San Antonio, TX. 11. Goldstein BJ, Fuell D, Menci L, Heise M, Freed M. Rosiglitazone in Combination With Glibenclamide: Effect on PAI-1 Antigen, PAI-1 Activity, and tPA in Patients With Type 2 Diabetes Mellitus. International Diabetes Federation Meeting, November, 2000, Mexico City, Mexico. 12. Wu X, Deeb W, Hoffstedt J, Arner P, Goldstein BJ. Increased Endogenous Activity of PTPases, Including PTP1B, in Human Omental vs. Subcutaneous Adipose Tissue May Contribute to Differential Insulin Responsiveness. American Diabetes Association Annual Mtg, June 2001, Philadelphia, PA. 13. Mahadev K, Zilbering A, Zhu L, Goldstein BJ. Insulin-Stimulated Generation of Hydrogen Peroxide Reversibly Inhibits PTP1B in vivo and Enhances the Early Insulin Action Cascade. American Diabetes Association Annual Mtg, June 2001, Philadelphia, PA. 14. Zhu L, Zilbering A, Wu X, Joseph JI, Jabbour A, Deeb W, Goldstein BJ. Use of an Anaerobic Environment Preserves the Endogenous Activity of Protein-Tyrosine Phosphatases Isolated from Insulin-Sensitive Cells. American Diabetes Association Annual Mtg, June 2001, Philadelphia, PA. 15. Goldstein BJ, Bruce S, Lee H, Fiedorek FT. Rosiglitazone Added to Glyburide/Metformin Tablets: Glycemic Effects. American Diabetes Association Annual Mtg, June 2002, San Francisco, CA 16. Bruce S, Lee H, Goldstein BJ. Incidence of Hypoglycemia Following Addition of Rosiglitazone to Glyburide/Metformin Tablets in Patients with Type 2 Diabetes. American Diabetes Association Annual Mtg, June 2002, San Francisco, CA 17. Mahadev K, Wu X, Motoshima H, Goldstein BJ. Integration of Multiple Downstream Signals Determines the Net Effect of Insulin on MAP Kinase vs. PI 3’-Kinase Activation: Potential Role of Insulin-Stimulated H2O2. (1318-P) American Diabetes Association Annual Mtg, June 2002, San Francisco, CA. 18. Zhu L, Zilbering A, Wu X, Mahadev K, Motoshima H, Hong S, Yao J, Goldstein BJ. Hyperglycemia Potentiates Insulin-Stimulated H2O2 Production and Enhances the Oxidative Inhibition of Thiol-Sensitive Protein-Tyrosine Phosphatases. (1878-P) American Diabetes Association Annual Mtg, June 2002, San Francisco, CA. 19. Wu X, Hardy VE, Joseph JI, Jabbour S, Mahadev K, Zhu L Goldstein BJ. Endogenous Protein-Tyrosine Phosphatase Activity in Human Adipocytes is Strongly Correlated with Insulin-Stimulated Glucose Uptake and is a Target of Insulin-Induced Oxidative Inhibition. (1248-P) American Diabetes Association Annual Mtg, June 2002, San Francisco, CA. 20. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ. Differential Regulation of Adiponectin Secretion from Cultured Human Omental and Subcutaneous Adipocytes: Effects of Insulin and Rosiglitazone. (357-P) American Diabetes Association Annual Mtg, June 2002, San Francisco, CA. 21. Wu XD, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Adiponectin Stimulates Glucose Uptake in Primary Rat Adipocytes Via an AMP-activated Protein Kinase-Coupled Mechanism. American Diabetes Association Annual Mtg, June 2003, New Orleans, LA. 22. Mahadev K, Motoshima H, Wu XD, Chen GJ, Lambeth JD, Goldstein BJ. Nox4, an NADPH Oxidase Homolog Highly Expressed in Insulin-Sensitive Cells, Modulates Insulin-Stimulated Generation of H2O2 and Plays an Integral Role in Insulin Signal Transduction. American Diabetes Association Annual Mtg, June 2003, New Orleans, LA. 23. Motoshima H, Wu XD, Mahadev K, Goldstein BJ. Adiponectin Stimulates AMP-Activated Protein Kinase in Endothelial Cells and Inhibits Oxidized LDL-Induced Proliferation by Reducing Cellular Superoxide Production. American Diabetes Association Annual Mtg, June 2003, New Orleans, LA. 24. Rosenstock J, Vinik A, Goldstein BJ, Porter LE, Heise MA, O’Neill MC, Dirani R, Kravitz B, Freed MI & the Rosiglitazone 135 Study Group, Type 2 Diabetes (T2DM) in the Elderly: Reaching Durable Glycemic Goals and Improved Health Outcomes with Combination Sulfonylurea (SU) and Rosiglitazone (RSG). American Diabetes Association Annual Mtg, June 2003, New Orleans, LA. 25. Weissman PN, Goldstein BJ, Campbell JC, Gould ER, Waterhouse BR, Wooddell MM, Cobitz SR. Favorable Effects of Rosiglitazone and Metformin Combination Therapy on CV Risk Markers Suggests Potential CV benefits in High Risk Type 2 Diabetics. American Diabetes Association Annual Mtg, June 2004, Orlando, FL. 26. Rosenstock J, Goldstein BJ, Cobitz AR, Waterhouse B, Wooddell M, Strow L. Greater Benefits of Rosiglitazone (RSG) Added to Sub-Maximal Dose of Metformin (MET) Compared to Maximizing Metformin Dose in Type 2 Diabetes Mellitus (T2DM) Patients. American Diabetes Association Annual Mtg, June 2004, Orlando, FL. 27. Motoshima H, Wu XD, Mahadev K, Hough K, Ouedraogo R, Goldstein BJ. Recombinant Globular Adiponectin Inhibits Oxidized LDL-induced Endothelial Cell Proliferation, Superoxide Generation and the Oxidation of Native LDL. American Diabetes Association Annual Mtg, June 2004, Orlando, FL. 28. Mahadev K, Motoshima H, Wu XD, Hough K, Yaakovian M, Lambeth JD, Goldstein BJ. Subcellular Co-localization and Functional Coupling Supports a Role for the NAD(P)H Oxidase Homolog Nox4 in the Regulation of PTP1B Catalytic Activity via Insulin-Stimulated H2O2. American Diabetes Association Annual Mtg, June 2004, Orlando, FL. 29. Wu XD, Zhu L, Mahadev K, Motoshima H, Zilbering A, Goldstein BJ. Increased Oxidant Generation and Protein-Tyrosine Phosphatase (PTPase) Inhibition by High Glucose Differentially Enhances Insulin Signaling in 3T3-L1 vs. Primary Rat Adipocytes Due to Inhibitory Effects of Protein Kinase C (PKC). American Diabetes Association Annual Mtg, June 2004, Orlando, FL. 30. O’Neill MC, Rosenstock J, Goldstein BJ, Wooddell M, Strow L, Waterhouse B, Cobitz AR. Greater Benefits of Rosiglitazone (RSG) Added to Sub-Maximal Dose of Metformin (MET) Compared to Maximizing Metformin Dose in Type 2 Diabetes Mellitus Patients. European Association for the Study of Diabetes, September 2004, Munich, Germany. 31. McCallum RW, Fogel R, Fang JC, Altman RS, Faichney JD, Goldstein BJ. Mitemcinal Fumarate (GM-611) Provided Symptomatic Relief of Diabetic Gastroparesis, Especially in Type 1 Diabetes: Results of a 12-Week, Multi-center, Double-blind, Placebo-controlled, Randomized Phase 2b Study (GM-611-05). American Gastrointestinal Association, May, 2005, Chicago, IL. 32. Rosenberg DE, Edman JS, Goldstein BJ, Falkner B. A Pilot Study of Chromium Supplementation Influences on Insulin Resistance and Glycemic Control in Type 2 Diabetes Mellitus. American Association of Clinical Endocrinologists Annual Meeting, May 2005, Washington, DC. 33. Wu XD, Mahadev K, Ouedraogo R, Hough K, Goldstein BJ. IkB kinase (IKKβ) is a Signaling Target of Insulin and Globular Adiponectin: Potential Role in Cytokine-Induced Insulin Resistance, American Diabetes Association Annual Mtg, June 2005, San Diego, CA. 34. Ouedraogo R, Motoshima H, Mahadev K, Wu XD, Hough K, Scalia R, Goldstein BJ. Adiponectin Suppression of High Glucose-Induced Superoxide Generation in Vascular Endothelial Cells: Evidence for Involvement of a cAMP Signaling Pathway, American Diabetes Association Annual Mtg, June 2005, San Diego, CA. 35. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Öhman P. Tesaglitazar Improves Glucose and Lipid Abnormalities in Patients with Type 2 Diabetes, American Diabetes Association Annual Mtg, June 2005, San Diego, CA. 36. McCallum RW, Goldstein BJ. Mitemcinal Fumarate in the Treatment of Symptomatic Diabetic Gastroparesis and Identification of Target Population in a 12-week, Multi-center, Double-blind, Placebo-controlled, Randomized Phase 2b Study (GM-611-05), American Motility Society Annual Mtg, Sept 2005, Santa Monica, CA. 37. Tao L, Gao E, Lopez B, Christopher T, Koch W, Goldstein B, Ma XL. Cardioprotective effects of adiponectin in ischemic/reperfusion injury and its mechanisms. American Heart Association Annual Mtg, Nov 2005, Dallas, TX. 38. Sharma K, Falkner B, Nocella L, Qiu G, Quedraogo R, Hough K, Dunn S, Chan L, Goldstein BJ. Adiponectin regulates albuminuria in humans and mice. Am Soc Nephrology Ann Mtg, Nov 2005, Philadelphia, PA. 39. McCallum RW, Goldstein BJ. Diabetic Gastroparesis : Effect of Mitemcinal by subgroup analysis in a 12-week, Randomized, Multi-center, Double-blind, Placebo-controlled, Phase 2b Study. Digestive Diseases Week, May 2006, Los Angeles, CA. 40. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Öhman P. Glucose and lipid responder rates and goal attainment with tesaglitazar in patients with type 2 diabetes. American Diabetes Association Annual Mtg, June 2006, Washington, DC 41. Goldstein BJ, Segiet T, Ferreira-Cornwell MC, Krebs JB, Chou HS. Initial Treatment with Rosiglitazone (RSG) and Glimepiride (GLIM) fixed-dose combination (FDC) reduces cardiovascular and inflammatory markers and improves insulin sensitivity in patients with type 2 diabetes (T2DM). American Diabetes Association Annual Mtg, June 2006, Washington, DC 42. Ouedraogo R, Hough K, Mahadev K, Wu XD, Gong Y, Chan L, Scalia R, Goldstein BJ. Leukocyte-Endothelial Interactions are Increased in the Mesenteric Microvasculature of Live Mice Deficient in Adiponectin. American Diabetes Association Annual Mtg, June 2006, Washington, DC 43. Mahadev K, Ruffolo S, Wu XD, Ouedraogo R, Kennedy BP, Goldstein BJ. Protein-Tyrosine Phosphatase 1B (PTP1B), a Target of Cellular Oxidative Inhibition Following Insulin Stimulation, Interacts with the NADPH Oxidase Homolog Nox4. American Diabetes Association Annual Mtg, June 2006, Washington, DC 44. Wu XD, Fuchsel L, Ouedraogo R, Mahadev K, Xu SQ, Goldstein BJ. Adiponectin Suppresses IkB kinase (IKKβ) Activation in Endothelial Cells via PKA and AMPK Signaling. American Diabetes Association Annual Mtg, June 2006, Washington, DC 45. Fuchsel L, Xu SQ, Wu XD, Mahadev K, Goldstein BJ Adiponectin Increases the Abundance of Manganese Superoxide Dismutase (MnSOD) via cAMP Signaling in Endothelial Cells: Potential Role in Suppression of Cellular Reactive Oxygen Species. American Diabetes Association Annual Mtg, June 2006, Washington, DC. 46. Qiu G, Ouedraogo R, Hough K, Zhu Y, Dunn S, Chan L, Goldstein BJ, Sharma K. Protective Role of Adiponectin in Kidney Disease. American Society of Nephrology Annual Mtg, Nov 2006. 47. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Öhman P. Glucose and lipid responder rates and goal attainment with tesaglitazar in patients with type 2 diabetes. European Association for the Study of Diabetes (EASD), Sept 2006, Copenhagen, Denmark 48. Williams-Herman D, Goldstein BJ, Feinglos MN, Lunceford J, Johnson J. Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin provides substantial glycemic improvement and HbA1c goal attainment in patients with type 2 diabetes mellitus, International Diabetes Federation Scientific Meeting, Dec 2006, Capetown, South Africa. 49. Mahadev K, Ouedraogo R, Wu XD, Eckhart AD, Goldstein BJ. Adiponectin Suppresses VEGF-Induced Endothelial Cell Migration via a cAMP/PKA Signaling Pathway. American Diabetes Association Annual Mtg, June 2007, Chicago, IL. 50. Xu S-Q, Mahadev K, Wu XD, Fuchsel L, Donnelly S, Goldstein BJ. Adiponectin Protects Against Angiotensin (Ang) II- or Tumor Necrosis Factor (TNF) α-induced Endothelial Monolayer Permeability via cAMP/PKA Signaling. American Diabetes Association Annual Mtg, June 2007, Chicago, IL. 51. Wu XD, Shaw MA, Patel V, Mahadev K, Hu C, Goldstein BJ. α-Enolase, Identified by a Thiol Proteome Screen, is a Novel Cellular Target of Insulin-Induced Reactive Oxygen Species (ROS) That Undergoes Insulin-Stimulated Translocation to the Plasma Membrane. American Diabetes Association Annual Mtg, June 2007, Chicago, IL. 52. Ouedraogo R, Berzins B, Wu XD, Mahadev K, Chan L, Henderson K, Goldstein BJ, Scalia R. Anti-Inflammatory Effects of Adiponectin on Leukocyte-Endothelium Interactions in Vivo Are Mediated By Enhanced Nitric Oxide Bioavailability and Suppression of Endothelial Cell Adhesion Molecule Expression. American Diabetes Association Annual Mtg, June 2007, Chicago, IL. 53. Mather KJ, Funahashi T, Edelstein S, Bray G, Kahn S, Crandall J, Marcovina S, Goldstein BJ, Goldberg R. Adiponectin and Change in Adiponectin Predict Diabetes Outcomes in the Diabetes Prevention Program. American Diabetes Association Annual Mtg, June 2007, Chicago, IL. 54. Florez JC, Jablonski KA, McAteer J, Sun MW, Pollin TI, de Bakker PIW, Hanson RL, Goldstein BJ, Horton E, Knowler WC, Nathan DM, Altshuler D for the DPP Research Group. Common Variants in the 7 AMP Kinase Genes and Progression to Diabetes in the Diabetes Prevention Program. American Diabetes Association Annual Mtg, June 2007, Chicago, IL. 55. Ma XL, Tao L, Gao E, Zhang H, Koch W, Lopez B, Christopher T, Chan L, Goldstein BJ. Essential Role of Adiponectin in Rosiglitazone’s Cardioprotection against Myocardial Ischemic Injury. American Heart Association Annual Mtg, November 2007, Orlando, FL. 56. Lancel S, Weinberg EO, Valsky E, Jeong MY, Farukhi Z, Pimentel DR, Mahadev K, Goldstein BJ, Pagano PJ, Siwik DA, Colucci WS. NADPH Oxidase 2 is Responsible for Alpha 1-Adrenergic Receptor Dependent Reactive Oxygen Species Production in Adult Rat Ventricular Myocytes. American Heart Association Annual Mtg, November 2007, Orlando, FL. 57. Yang X, Liu H, Peng W, Zhang J, Yan L, Wu Y, Wu XD, Goldstein BJ, Ma XL. Presence of Auto-antibody against Angiotensin II Receptor in Pregnant Women and Its Potential Role in the Development of Preeclampsia. American Heart Association Annual Mtg, November 2007, Orlando, FL MANUSCRIPTS SUBMITTED OR IN PREPARATION
1. Mahadev K, Ruffolo S, Wu, XD, Ouedraogo R, Kennedy BP, Goldstein BJ. Protein-Tyrosine Phosphatase 1B, a Target of Cellular Oxidative Inhibition, Directly Interacts With the NADPH Oxidase Homolog Nox4, submitted 2. Sharma K, Qiu G, Zhu Y, RamachandraRao S, Usui HK, Dunn SR Ouedraogo R, Hough K, McCue P, Chan L Falkner B, Goldstein BJ. Adiponectin and Albuminuria: A Potential Causative Link Between Obesity and the Kidney, submitted 3. Mahadev K, Wu XD, Ouedraogo R, Kennedy BP, Eckhart AD, Goldstein BJ. Adiponectin Inhibits Vascular Endothelial Growth Factor-Induced Migration of Human Coronary Artery Endothelial Cells, submitted. 4. Wu XD, Fuchsel L, Ouedraogo R, Mahadev K, Xu S-Q, Goldstein BJ. Adiponectin Suppresses IkB Kinase Activation Induced by Tumor Necrosis Factor-α or High Glucose in Endothelial Cells: Role of cAMP and AMP Kinase Signaling, in revision. 5. Xu S-Q, Mahadev K, Wu XD, Fuchsel L, Donnelly S, Goldstein BJ. Adiponectin Protects Against Angiotensin II or Tumor Necrosis Factor α-induced Endothelial Cell Monolayer Hyperpermeability: Role of cAMP/PKA Signaling, submitted.. RECENT INVITED LECTURES (2002-)
1. Symposium Lecture, Faculty Update Conference, Orlando, FL, 2/8/02, “Thiazolidinediones: Complementary Roles in Cardiology Practice.” 2. Symposium Lectures, Endocrinology 2002 Update, Gold Coast, Australia, 3/2/02, “Insulin Resistance: A Key Defect in Type 2 Diabetes” and “Role of Thiazolidinediones in the Management of Type 2 Diabetes.” 3. ADA CME Symposium Lecture, Diabetes Update 2002, Newark, Delaware, 3/23/02, “The Concept of Insulin Resistance – Its Importance in Diabetes Management.” 4. CME lecture sponsored by the Joslin Diabetes Center, Baltimore, MD, 5/1/02, “Type 2 Diabetes & Cardiovascular Disease: Complications of Insulin Resistance”. 5. Endocrine Grand Rounds, Oregon Health Sciences University, Portland, OR, 5/13/02, “Novel Therapeutic Targets for Insulin Resistance in the Metabolic Syndrome.” 6. Medical Grand Rounds, Adventist Medical Center, Portland, OR, 5/14/02, “Role of Thiazolidinediones in the Management of Type 2 Diabetes and the Metabolic Syndrome.” 7. Invited Speaker, Annual Scientific Meeting of the American Diabetes Association, San Francisco, CA, 6/16/02.Current Issues: “Radical Signals: The role of reactive oxygen species in insulin action.” 8. CME symposium lecture, Primary Care Medicine West Symposium on Re-Evaluating Treatment Strategies for Type 2 Diabetes, Chicago, IL, 6/19/02, “Therapeutic approaches and long-term management of type 2 diabetes and cardiovascular disease.” 9. CME symposium chairperson and speaker, Type 2 Diabetes to Cardiovascular Disease, The Endocrine Society CME Series, Detroit, MI 9/14/02 and New York, NY 10/05/02, “Insulin Resistance.” 10. International Diabetes Teaching Faculty Development Program Co-Chairman and Lecturer, Toronto, Canada and Barcelona, Spain, 9/20/02 and 12/6/02. 11. CEU lecture, Diabetes Mellitus Series, Department of Nursing, Thomas Jefferson University Hospital, Philadelphia, PA, 10/02/02, “Complications of Diabetes.” 12. CME symposium Co-chairperson and speaker, “Treating to Target in Type 2 Diabetes”, Sponsored by Thomas Jefferson University CME, Chicago, IL 10/26/02 and Atlanta, GA 11/09/02. 13. Medical Grand Rounds, The Medical Center, Beaver, PA, 11/8/02, “Role of Thiazolidinediones in the Management of Type 2 Diabetes and the Metabolic Syndrome.” 14. CME symposium lecture, Preferred Care Health System, Rochester, NY, 11/14/02, “The Metabolic *Syndrome and its Clinical Management.” 15. CME symposium lecture, Primary Care Medicine Mid-Atlantic Symposium on Re-Evaluating Treatment Strategies for Type 2 Diabetes, Washington, DC, 11/22/02, “Therapeutic Approaches and Long-term Management of Type 2 Diabetes and Cardiovascular Disease.” 16. CME symposium lecture, American College of Cardiology Snowmass Cardiovascular Conference, Aspen, CO, 1/17/03, “Optimal Therapeutic Approaches for the Management of Type 2 Diabetes and the Metabolic Syndrome.” 17. CME symposium lecture, ‘Take Care of Your Diabetes’ Physician Symposium, Wilmington, DE, 1/21/03, “Practical Strategies for Insulin Therapy in Type 2 Diabetes.” 18. Symposium Co-Chairman and Lecturer, ‘Take Care of Your Diabetes’ Patient education symposium, Philadelphia, PA, 2/22/03, “Can Type 2 Diabetes be Prevented – The Results are in!” 19. Research Lecture, Centocor, Radnor, PA, 2/25/03, “Role of Adipose Tissue Secretory Products in Insulin Resistance and Type 2 Diabetes.” 20. Longwood Area Diabetes/Metabolism Clinical CME Conference, Joslin Diabetes Center, Harvard Medical School, Boston, MA, 3/24/03, “Role of Adipose Tissue Secretory Products in Insulin Resistance and Type 2 Diabetes.” 21. Endocrinology Grand Rounds, Tufts University / New England Medical Center, Boston, MA 3/25/03, “Reciprocal Regulation of Insulin Signal Transduction by Protein-Tyrosine Phosphatases.” 22. Endocrinology Grand Rounds, Boston University Medical Center, Boston, MA 3/25/03, “Effects of Thiazolidinediones on Adipose Tissue Secretory Products in the Management of Insulin Resistance in Type 2 Diabetes.” 23. CME Symposium chairman and lecture sponsored by the Endocrine Society, American College of Physicians Annual Meeting, on Taking Insulin Resistance to Heart: Translating the Vascular Profile into Clinical Outcomes, “Therapeutic Approaches and Long-Term Management of Type 2 Diabetes and Cardiovascular Disease.” San Diego, CA, 4/2/03. 24. CME lecture sponsored by the Endocrine Society, Primary Care Medicine West Symposium on Progression of Type 2 Diabetes and the Continuum of Care: A Case-based Program, “The Role of Combination Therapy.” Long Beach, CA, 4/3/03. 25. CME symposium chairperson and speaker, “From Guidelines to Practice: Achieving Type 2 Diabetes Goals in Primary Care”, Sponsored by Thomas Jefferson University CME, New York, NY 4/5/03 and Washington, DC 4/12/03. 26. Endocrinology Grand Rounds, Temple University Medical Center, Philadelphia, PA 4/22/03, “Regulation of Insulin Signal Transduction by Protein-Tyrosine Phosphatases and its Clinical Implications.” 27. Endocrinology Grand Rounds, University of Buffalo and VA Medical Center, Buffalo, NY 4/29/03, “Role of Adipose Tissue Secretory Products in the Pathogenesis of Insulin Resistance and Type 2 Diabetes.” 28. State-of-the-Art Lecture, American Diabetes Association Scientific Sessions, New Orleans, LA 6/17/03, “Treatment of Insulin Resistance: Implications for Type 2 Diabetes and Cardiovascular Disease.” 29. Symposium Lecture, National Black Nurses Association, New Orleans, LA 7/31/03, “Use of Combination Oral Therapy and Insulin to Reach Glucose Goals in Type 2 Diabetes.” 30. CME Board Review lecture sponsored by Jefferson Medical College and the American College of Physicians, “Endocrinology.” Philadelphia, PA, 9/13/03. 31. International Diabetes Teaching Faculty Development Program Co-Chairman and Lecturer, Barcelona, Spain, 10/3/03. 32. CME symposium chairperson and speaker, sponsored by the Endocrine Society, Primary Care Medicine Symposium on Progression of Type 2 Diabetes and the Continuum of Care: A Case-based Program, “Consequences of the Disease Continuum.” Washington, DC, 10/18/03. 33. CME symposium chairperson and speaker, “From Guidelines to Practice: Achieving Type 2 Diabetes Goals in Primary Care”, Sponsored by Thomas Jefferson University CME, Sacramento, CA, NY 11/1/03. 34. CME symposium chairperson and speaker, sponsored by the Endocrine Society, Primary Care Medicine Symposium on Progression of Type 2 Diabetes and the Continuum of Care: A Case-based Program, “Consequences of the Disease Continuum.” Boston, MA 11/6/03. 35. CME Webcast symposium speaker, “Achieving and Sustaining Glycemic Control in Type 2 Diabetes: Medical Aspects of Type 2 Diabetes” sponsored by CADRE, 11/11/03. 36. CME symposium speaker, “Can Type 2 Diabetes be Prevented? The Data are in!” Diabetes Association of Greater Cleveland, Cleveland, OH 11/13/03. 37. Endocrinology Grand Rounds, Case Western University Hospital, Cleveland, OH 11/13/03, “Obesity, Insulin Resistance and Type 2 Diabetes: Causes, Consequences and Management.” 38. CME lecture sponsored by the Joslin Diabetes Center, New York, NY, 12/8/03, “Type 2 Diabetes: Tools for Clinical Intervention.” 39. CME lecture, Morristown Memorial Hospital, Morristown, NJ, 12/17/03, “Role of Hyperglycemia in the Cardiovascular Complications of Type 2 Diabetes.” 40. CME lecture, Institute for Insulin Resistance Studies Symposium, Nassau, Bahamas, 1/28/04, “Insulin Resistance in Type 2 Diabetes: Pathogenesis and Treatment Approaches.” 41. Invited Speaker, 2nd International Conference on NADPH Oxidases, Pine Mountain, GA, 3/31/04, “Insulin-Stimulated ROS Generation and Insulin Signaling: Role of Nox4.” 42. Invited Speaker, New York Lipid Club Meeting, New York, NY, 4/28/04, “Insulin-Stimulated H2O2 Generation Facilitates the Insulin Signaling Cascade by Oxidative Inhibition of PTPases.” 43. CME Symposium Co-Chairman and Speaker, Radnor, PA, 5/1/04, “Current Role of Combination Oral Antidiabetic Drugs to Manage Patients with Type 2 Diabetes.” 44. Grand Rounds Lecture, Kumamoto University School of Medicine, Kumamoto, Japan, 5/10/04, “Role of Nox4 in Insulin-Stimulated ROS Generation and Regulation of Reversible Tyrosine Phosphorylation.” 45. Invited Symposium Speaker, Japanese Diabetes Society Annual Scientific Meeting, Tokyo, Japan, 5/13/04, “Insulin Resistance, Type 2 Diabetes and Cardiovascular Disease: Role of the Thiazolidinediones.” 46. Medical Grand Rounds, Coatesville VA Medical Center, Coatesville, PA, 6/2/04, “Role of Hyperglycemia in the Cardiovascular Complications of Type 2 Diabetes.” 47. CME Symposium Co-Chairman and Speaker, New York City, NY, 6/12/04, “Current Role of Combination Oral Antidiabetic Drugs to Manage Patients with Type 2 Diabetes.” 48. CME Symposium Chairman, The Endocrine Society Annual Meeting, New Orleans, LA, 6/17/04, “Type 2 Diabetes: Rationale for Earlier Use of Combination Therapy.” 49. CME Symposium Co-Chairman and Speaker, Harrisburg, PA, 6/20/04, “Current Role of Combination Oral Antidiabetic Drugs to Manage Patients with Type 2 Diabetes.” 50. CME Symposium, Endocrine Society of Argentina, Buenos Aires, Argentina, 7/12/04, “New Developments in the Diagnosis and Management of Type 2 Diabetes.” 51. CME Symposium, Santiago and Concepción, Chile, 7/13 and 7/15/04, “Rationale for the Early and Aggressive Management of Type 2 Diabetes.” 52. CME Symposium Co-Chairman and Speaker, Columbia, SC, 7/24/04, “Current Role of Combination Oral Antidiabetic Drugs to Manage Patients with Type 2 Diabetes.” 53. CME Board Review lecture sponsored by Jefferson Medical College and the American College of Physicians, “Endocrinology.” Philadelphia, PA, 9/11/04. 54. Medical Grand Rounds, White Plains Hospital, White Plains, NY, 10/5/04, “Early Aggressive Management of Type 2 Diabetes: Role of the Thiazolidinediones.” 55. Medical Grand Rounds, Coatesville VA Medical Center, Coatesville, PA, 10/27/04, “Role of Hyperglycemia in the Cardiovascular Complications of Type 2 Diabetes, Part II.” 56. CME Symposium Speaker, Diabetes Technology Society Annual Scientific Meeting, Philadelphia, PA, 10/28/04, “Multifactorial Risk Factor Reduction in Type 2 Diabetes.” 57. Endocrine Grand Rounds, Memorial Sloan-Kettering Cancer Center, 11/3/04, "Adiponectin – A Novel ‘Adipocytokine’ with Metabolic and Vascular Effects." 58. CME Symposium Speaker, American Heart Association Annual Scientific Meeting, New Orleans, LA 11/8/04, “Identifying MetSyn as a Risk Factor for Type 2 Diabetes: Implications for Cardiologists." 59. Endocrine Grand Rounds, Albert Einstein College of Medicine, New York, NY, 1/7/05, “Reciprocal Regulation of Protein-Tyrosine Phosphatases and the Insulin Signaling Pathway.” 60. Endocrine Grand Rounds, University of California at Los Angeles, 1/12/05, "Adiponectin – A Novel ‘Adipocytokine’ with Metabolic and Vascular Effects." 61. Endocrine Grand Rounds, Baylor College of Medicine, Houston, TX 2/3/05, “Reciprocal Regulation of Protein-Tyrosine Phosphatases and the Insulin Signaling Pathway.” 62. Cardiology Grand Rounds, Mount Sinai School of Medicine, New York, NY, 2/7/05, “Cardiovascular Risk in the Spectrum of Type 2 Diabetes." 63. CME Lecture, Philadelphia International Medicine, Telecast from Jefferson to Prince Faisal Hospital, Saudi Arabia, 2/22/05, “Cardiovascular Risk in the Spectrum of Type 2 Diabetes." 64. CME Symposium Speaker, American College of Cardiology Annual Meeting, Orlando, CA 3/5/05, “Atherosclerosis and the Insulin Resistance: Piecing Together the Mystery of the Metabolic Syndrome.” 65. Conference Speaker, Grantees meeting for RFA-HL-04-013, NHLBI, NIH, Bethesda, MD, 3/14/05, “Adiponectin Improves Endothelial Function in High Glucose.” 66. Endocrine Grand Rounds, Diabetes Branch, NIDDK, National Institutes of Health, Bethesda, MD, 3/25/05, “Regulation of Protein-Tyrosine Phosphatases and the Insulin Signaling Pathway by Insulin-Stimulated Reactive Oxygen Species.” 67. Symposium Speaker, 40th Annual Meeting of the German Diabetes Association, Berlin, Germany, 5/6/05, “Insulin-stimulated Generation of Reactive Oxygen Species and Insulin Signaling: Novel Molecular Pathways.” 68. CME Board Review lecture sponsored by Jefferson Medical College and the American College of Physicians, “Endocrinology.” Philadelphia, PA, 9/10/05. 69. Symposium Speaker, Annual Meeting of the Endocrine Society of Thailand, Bangkok, Thailand, 9/22/05, "Early and Aggressive Therapy to Glycemic Goals and Reduce Cardiovascular Risk in Type 2 Diabetes." 70. Lecturer, Taiwan Diabetes Association Fall Scientific Meeting, Buddhist Tzu Chi General Hospital, Hawlian, Taiwan, 9/24/05, “The Role and Regulation of Protein Phosphatases in Insulin Action.” 71. Symposium Speaker, Taiwan Society of Lipids & Atherosclerosis, Taipei, Taiwan, 9/25/05, “Combination Therapy with TZDs in Type 2 Diabetes and Cardiovascular Disease.” 72. Symposium Speaker, Taiwan Society of Lipids & Atherosclerosis, Taipei, Taiwan, 9/25/05, “How to Increase the Success Rate of Submissions of Research Papers for Publication”. 73. Translational Medicine Seminar, Department of Medicine, Jefferson Medical College, 10/14/05, “The Role and Regulation of Protein Phosphatases in Insulin Action.” 74. Research Seminar, Department of Physiology, Jefferson Medical College, 2/2/06, “Obesity and Endothelial Function: Role of Adiponectin.” 75. CME Lecture, Philadelphia International Medicine, Telecast from Jefferson to Saudi Arabia, United Arab Emirates and Brazil, 2/7/06, “Cardiovascular Risk in Type 2 Diabetes: New Therapeutic Approaches." 76. CME Lecture, American Association of Clinical Endocrinologists New Jersey Chapter, Bridgewater, NJ, 3/1/2006, "Novel Drug Targets for Insulin Resistance and Type 2 Diabetes: PTP1B and Adiponectin." 77. National Diabetes Teaching Faculty Development Program Lecturer, Orlando, FL, 4/1/06, .”Frequently Asked Questions About Thiazolidinedione Use in Type 2 Diabetes.” 78. CME Symposium Speaker, American College of Physicians, Philadelphia, PA 4/6/06, “TZDs: Balancing Treatment Options with Patient Outcomes.” 79. CME Symposium Speaker, American College of Clinical Endocrinologists, Chicago, IL, 4/26/06, “From Science to Applications for Clinicians.” 80. Keynote Lecture, 8th Annual Meeting of the Diabetes in Pregnancy Study Group of North America, Cleveland, OH, 5/5/06, “Adiposity, Insulin Sensitivity and Vascular Function: Focus on Adiponectin.” 81. CME Symposium Chairman and Speaker, American Diabetes Association 2006 Scientific Sessions, Washington, DC, 6/12/06, “Updating the Management of Type 2 Diabetes and the Metabolic Syndrome: Treating Hyperglycemia in Insulin-Resistant Patients.” 82. Symposium Speaker, American Diabetes Association 2006 Scientific Sessions, Washington, DC, 6/9/06, “Insulin-Stimulated Reactive Oxygen Species and Insulin Signaling.” 83. Symposium Speaker, European Association for the Study of Diabetes (EASD), Copenhagen, Denmark, 9/13/06, “Optimizing Management of Diabetes – A Multifactorial Approach; PPAR Agonists – What do Clinical Studies Show?” 84. CME Symposium Speaker, Parsippany, NJ, 9/30/06, “Multi-Component Interventions for the Patient With Type 2 Diabetes and Comorbidities.” 85. Invited Speaker, Gordon Research Conference on NOX Family NADPH Oxidases, Les Diablerets, Switzerland, 10/19/06, “Role of NOX4 in the Regulation of Insulin Signaling via Oxidative Inhibition of Downstream Targets.” 86. Invited Speaker, Aware for All program for Clinical Research Education and Awareness Day, Philadelphia, PA, 11/4/06, “Clinical research in Diabetes.” 87. CME Lecture, Pri-Med Update, Sacramento, CA 11/30/06 and Harrisburg, PA 12/14/06, "Incretin Enhancers and DPP-IV Inhibitors: Novel Treatments for Type 2 Diabetes." 88. Endocrinology Grand Rounds, Boston University Medical Center, Boston, MA 12/11/06, “Insulin-Stimulated Reactive Oxygen Species and Insulin Signaling: Molecular Targets.” 89. Vascular/SCOR conference, Columbia University School of Medicine, New York, NY 12/20/06, “Obesity and Endothelial Function: Role of Adiponectin.” 90. Endocrinology Grand Rounds, Naomi Berrie Diabetes Center, Columbia University School of Medicine, New York, NY 12/21/06, “Insulin-stimulated Generation of Reactive Oxygen Species and Insulin Signaling: Novel Molecular Pathways.” 91. Medical Grand Rounds, Graduate Hospital, Philadelphia, PA, 2/19/07, “Cardiometabolic Risk Reduction in Obesity: Role of the Endocannabinoid System.” 92. Medical Grand Rounds, Abington Hospital, Abington, PA, 2/21/07, “Early and Aggressive Management of Type 2 Diabetes: Clinical Approach” 93. CME Lectures, Pri-Med Update, East Rutherford, NJ 3/20/07 and Philadelphia, PA 4/13/07, "Redefining the Healthy Patient – New Outcomes Data in Type 2 Diabetes.” 94. Symposium CME Lecture, Annual Regional Update, American Diabetes Association, Newark, DE, 3/24/07, “Cardiometabolic Risk Reduction in Obesity: Role of the Endocannabinoid System.” 95. Best Practices CME Symposium Lecture,. New York, NY, 3/31/07, “Applications of New Outcomes Data for the Patient with Type 2 Diabetes.” 96. Department of Surgery Research Seminar, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, 4/18/07, “Adipose Tissue: the Good, the Bad, and the Ugly.” 97. Symposium Lecture, American Diabetes Association, Annual Scientific Sessions Chicago, IL 6/24/07, “Early and Initial Combination Therapy for Goal Achievement in T2DM” 98. Panel Discussion, Special Session, American Diabetes Association, Annual Scientific Sessions Chicago, IL 6/24/07, “Rosiglitazone and Cardiovascular Risk; Science and Public Health” 99. Continuing Education Symposium for Latin America, Co-Chair and Keynote Speaker, Mexico City, Mexico, 6/14/07, ”PPARγ and the Diabetes Continuum.” 100.

Source: http://jdc.jefferson.edu/barry_goldstein/cv.pdf